



US009211107B2

(12) **United States Patent**
Cox et al.

(10) **Patent No.:** **US 9,211,107 B2**
(45) **Date of Patent:** **Dec. 15, 2015**

(54) **RUGGEDIZED ULTRASOUND HYDROGEL INSERT**

(71) Applicant: **C. R. Bard, Inc.**, Murray Hill, NJ (US)

(72) Inventors: **Jeremy B. Cox**, Salt Lake City, UT (US); **Glen E. Southard**, Park City, UT (US); **Shayne Messerly**, Kaysville, UT (US)

(73) Assignee: **C. R. Bard, Inc.**, Murray Hill, NJ (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **13/671,382**

(22) Filed: **Nov. 7, 2012**

(65) **Prior Publication Data**

US 2013/0116571 A1 May 9, 2013

Related U.S. Application Data

(60) Provisional application No. 61/556,626, filed on Nov. 7, 2011, provisional application No. 61/563,382, filed on Nov. 23, 2011.

(51) **Int. Cl.**

A61K 49/00 (2006.01)
A61B 8/00 (2006.01)
B29C 39/00 (2006.01)

(Continued)

(52) **U.S. Cl.**

CPC **A61B 8/4281** (2013.01); **A61B 8/4444** (2013.01); **A61B 8/4483** (2013.01); **B29C 39/003** (2013.01); **C08J 3/075** (2013.01); **A61K 49/22** (2013.01); **C08J 2305/00** (2013.01); **C08L 5/00** (2013.01)

(58) **Field of Classification Search**

CPC A61K 49/22
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,133,244 A 5/1964 Wojtulewicz
3,297,020 A 1/1967 Mathiesen

(Continued)

FOREIGN PATENT DOCUMENTS

AU 642647 11/1990
AU 1860597 B2 6/1999

(Continued)

OTHER PUBLICATIONS

Rutala, Guideline for Disinfection and Sterilization in Healthcare Facilities, 2008.*

(Continued)

Primary Examiner — Paul Dickinson


(74) *Attorney, Agent, or Firm* — Rutan & Tucker, LLP

(57)

ABSTRACT

A ruggedized hydrogel product that is formulated to withstand the effects of high-energy sterilization procedures, such as gamma beam and electron beam sterilization, without significant structural degradation is disclosed. This enables the hydrogel product to be suitable for use in medical applications where sterile components are required. In one embodiment a ruggedized hydrogel product is disclosed and comprises a gel component, water for hydrating the gel component, and at least one free radical absorber component that is capable of absorbing free radicals produced when the hydrogel product is sterilized via a high-energy sterilization procedure. The free radical absorber component in one embodiment includes potassium metabisulfite and ascorbic acid. The ruggedized hydrogel product can be included with an ultrasound probe to provide an acoustically transparent interface between the probe and the skin of a patient.

7 Claims, 9 Drawing Sheets



- (51) **Int. Cl.**
C08J 3/075 (2006.01)
A61K 49/22 (2006.01)
C08L 5/00 (2006.01)

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,625,200	A	12/1971	Muller	4,793,361	A	12/1988	DuFault
3,674,014	A	7/1972	Tillander et al.	4,794,930	A	1/1989	Machida et al.
3,817,241	A	6/1974	Grausz	4,796,632	A	1/1989	Boyd et al.
3,847,157	A	11/1974	Caillouette et al.	4,798,588	A	1/1989	Aillon
3,868,565	A	2/1975	Kuipers	4,798,598	A	1/1989	Bonello et al.
3,902,501	A	9/1975	Citron et al.	4,809,681	A	3/1989	Kantrowitz et al.
3,995,623	A	12/1976	Blake et al.	4,809,713	A	3/1989	Grayzel
4,003,369	A	1/1977	Heilman et al.	4,813,729	A	3/1989	Speckhart
4,063,561	A	12/1977	McKenna	4,821,731	A	4/1989	Martinelli et al.
4,072,146	A	2/1978	Howes	4,836,214	A	6/1989	Sramek
4,114,601	A	9/1978	Abels	4,840,622	A	6/1989	Hardy
4,149,535	A	4/1979	Volder et al.	4,849,692	A	7/1989	Blood
4,173,228	A	11/1979	Van Steenwyk et al.	4,850,358	A	7/1989	Millar
4,175,566	A	11/1979	Millar	4,852,580	A	8/1989	Wood
4,181,120	A	1/1980	Kunii et al.	4,856,317	A	8/1989	Pidorenko et al.
4,224,949	A	9/1980	Scott et al.	4,856,529	A	8/1989	Segal
4,244,362	A	1/1981	Anderson	4,860,757	A	8/1989	Lynch et al.
4,289,139	A	9/1981	Enjoji et al.	4,867,169	A	9/1989	Machida et al.
4,317,078	A	2/1982	Weed et al.	4,869,263	A	9/1989	Segal et al.
4,327,722	A	5/1982	Groshong et al.	4,869,718	A	9/1989	Brader
4,362,166	A	12/1982	Furler et al.	4,887,606	A	12/1989	Yock et al.
4,365,639	A	12/1982	Goldreyer	4,887,615	A	12/1989	Taylor
4,380,237	A	4/1983	Newbower	4,889,128	A	12/1989	Millar
4,407,294	A	10/1983	Vilkomerson	4,899,756	A	2/1990	Sonek
4,429,693	A	2/1984	Blake et al.	4,901,725	A	2/1990	Nappholz et al.
4,431,005	A	2/1984	McCormick	4,905,698	A	3/1990	Strohl, Jr. et al.
4,431,214	A	2/1984	Buffington	4,911,173	A	3/1990	Terwilliger
4,445,501	A	5/1984	Bresler	4,911,174	A	3/1990	Pederson et al.
4,459,854	A	7/1984	Richardson et al.	4,924,870	A	5/1990	Wlodarczyk et al.
4,469,106	A	9/1984	Harui	4,943,770	A	7/1990	Ashley-Rollman et al.
4,483,343	A	11/1984	Beyer et al.	4,945,305	A	7/1990	Blood
4,491,137	A	1/1985	Jingu	4,947,852	A	8/1990	Nassi et al.
4,565,201	A	1/1986	Lass	4,957,111	A	9/1990	Millar
4,572,198	A	2/1986	Codrington	4,961,433	A	10/1990	Christian
4,577,634	A	3/1986	Gessman	4,966,148	A	10/1990	Millar
4,582,067	A	4/1986	Silverstein et al.	4,967,753	A	11/1990	Haase et al.
4,588,394	A	5/1986	Schulte et al.	4,977,886	A	12/1990	Takehana et al.
4,593,687	A	6/1986	Gray	4,989,608	A	2/1991	Ratner
4,595,012	A	6/1986	Webler et al.	4,995,396	A	2/1991	Inaba et al.
4,601,706	A	7/1986	Aillon	4,998,916	A	3/1991	Hammerslag et al.
4,608,989	A	9/1986	Drue	5,005,592	A	4/1991	Cartmell
4,608,992	A	9/1986	Hakim et al.	5,016,173	A	5/1991	Kenet et al.
4,619,247	A	10/1986	Inoue et al.	5,025,799	A	6/1991	Wilson
4,622,644	A	11/1986	Hansen	5,029,585	A	7/1991	Lieber et al.
4,644,960	A	2/1987	Johans	5,040,548	A	8/1991	Yock
4,652,820	A	3/1987	Maresca	5,042,486	A	8/1991	Pfeiler et al.
4,665,925	A	5/1987	Millar	5,045,071	A	9/1991	McCormick et al.
4,667,230	A	5/1987	Arakawa et al.	5,046,497	A	9/1991	Millar
4,674,518	A	6/1987	Salo	5,050,607	A	9/1991	Bradley et al.
4,676,249	A	6/1987	Arenas et al.	5,057,095	A	10/1991	Fabian
4,681,106	A	7/1987	Kensley et al.	5,058,595	A	10/1991	Kern
4,681,117	A	7/1987	Brodman et al.	5,067,489	A	11/1991	Lind
4,688,578	A	8/1987	Takano et al.	5,076,278	A	12/1991	Vilkomerson et al.
4,692,148	A	9/1987	Kantrowitz et al.	5,078,140	A	1/1992	Kwoh
4,697,595	A	10/1987	Breyer et al.	5,078,148	A	1/1992	Nassi et al.
4,700,997	A	10/1987	Strand	5,078,149	A	1/1992	Katsumata et al.
4,706,681	A	11/1987	Breyer et al.	5,078,678	A	1/1992	Katims
4,710,708	A	12/1987	Rorden et al.	5,078,714	A	1/1992	Katims
4,733,669	A	3/1988	Segal	5,084,022	A	1/1992	Claude
4,737,794	A	4/1988	Jones	5,092,341	A	3/1992	Kelen
4,741,356	A	5/1988	Letzo et al.	5,099,845	A	3/1992	Besz et al.
4,742,356	A	5/1988	Kuipers	5,099,850	A	3/1992	Matsui et al.
4,753,247	A	6/1988	Kirsner et al.	5,100,387	A	3/1992	Ng
4,770,185	A	9/1988	Silverstein et al.	5,105,829	A	4/1992	Fabian et al.
4,771,788	A	9/1988	Millar	5,109,862	A	5/1992	Kelen et al.
4,781,685	A	11/1988	Lehmann et al.	5,114,401	A	5/1992	Stuart et al.
4,784,646	A	11/1988	Feingold	5,121,750	A	6/1992	Katims
4,787,070	A	11/1988	Suzuki et al.	D327,740	S	7/1992	Arioka et al.
4,787,396	A	11/1988	Pidorenko	5,134,370	A	7/1992	Jefferts et al.
				5,144,955	A	9/1992	O'Hara
				5,158,086	A	10/1992	Brown et al.
				5,160,342	A	11/1992	Reger et al.
				5,161,536	A	11/1992	Vilkomerson et al.
				5,174,295	A	12/1992	Christian et al.
				5,184,601	A	2/1993	Putman
				5,190,045	A	3/1993	Frazin
				5,202,985	A	4/1993	Goyal
				5,211,165	A	5/1993	Dumoulin et al.
				5,211,636	A	5/1993	Mische

(56)

References Cited

U.S. PATENT DOCUMENTS

5,212,988 A	5/1993	White et al.	5,453,575 A	9/1995	O'Donnell et al.
5,214,615 A	5/1993	Bauer	5,456,256 A	10/1995	Schneider et al.
5,217,026 A	6/1993	Stoy et al.	5,456,718 A	10/1995	Szymaitis
5,220,924 A	6/1993	Frazin	5,464,016 A	11/1995	Nicholas et al.
5,235,987 A	8/1993	Wolfe	5,474,065 A	12/1995	Meathrel et al.
5,239,464 A	8/1993	Blair et al.	5,476,090 A	12/1995	Kishi
5,240,004 A	8/1993	Walinsky et al.	5,480,422 A	1/1996	Ben-Haim
5,243,995 A	9/1993	Maier	5,487,729 A	1/1996	Avellanet et al.
5,246,007 A	9/1993	Frisbie et al.	5,490,522 A	2/1996	Dardel
5,247,171 A	9/1993	Wlodarczyk et al.	5,492,538 A	2/1996	Johlin, Jr.
5,251,635 A	10/1993	Dumoulin et al.	5,494,038 A	2/1996	Wang et al.
5,255,680 A	10/1993	Darrow et al.	5,500,012 A	3/1996	Brucker et al.
5,257,636 A	11/1993	White	5,505,205 A	4/1996	Solomon et al.
5,257,979 A	11/1993	Jagpal	5,509,822 A	4/1996	Negus et al.
5,261,409 A	11/1993	Dardel	5,513,637 A	5/1996	Twiss et al.
5,265,610 A	11/1993	Darrow et al.	5,515,853 A	5/1996	Smith et al.
5,265,614 A	11/1993	Hayakawa et al.	5,522,878 A	6/1996	Montecalvo et al.
5,267,569 A	12/1993	Lienhard	5,526,812 A	6/1996	Dumoulin et al.
5,270,810 A	12/1993	Nishimura	5,531,664 A	7/1996	Adachi et al.
5,271,404 A	12/1993	Corl et al.	5,540,033 A	7/1996	Fox et al.
5,273,025 A	12/1993	Sakiyama et al.	5,540,230 A	7/1996	Vilkomerson
5,273,042 A	12/1993	Lynch et al.	5,540,681 A	7/1996	Strul et al.
5,274,551 A	12/1993	Corby, Jr.	5,542,938 A	8/1996	Avellanet et al.
5,275,053 A	1/1994	Wlodarczyk et al.	5,546,949 A	8/1996	Frazin et al.
5,279,129 A	1/1994	Ito	5,546,951 A	8/1996	Ben-Haim
5,279,607 A	1/1994	Schentag et al.	5,558,091 A	9/1996	Acker et al.
5,280,786 A	1/1994	Wlodarczyk et al.	5,568,809 A	10/1996	Ben-haim
5,287,331 A	2/1994	Schindel et al.	D375,450 S	11/1996	Bidwell et al.
5,289,373 A	2/1994	Zarge et al.	5,570,671 A	11/1996	Hickey
5,292,342 A	3/1994	Nelson et al.	5,575,291 A	11/1996	Hayakawa et al.
5,307,072 A	4/1994	Jones, Jr.	5,583,286 A	12/1996	Matsuyama
5,311,871 A	5/1994	Yock	5,588,442 A	12/1996	Scovil et al.
5,313,949 A	5/1994	Yock	5,592,939 A	1/1997	Martinelli
5,318,025 A	6/1994	Dumoulin et al.	5,598,846 A	2/1997	Peszynski
5,325,860 A	7/1994	Seward et al.	5,599,299 A	2/1997	Weaver et al.
5,325,873 A	7/1994	Hirschi et al.	5,600,330 A	2/1997	Blood
5,330,496 A	7/1994	Alferness	5,610,967 A	3/1997	Moorman et al.
5,331,966 A	7/1994	Bennett et al.	5,617,866 A	4/1997	Marian, Jr.
5,333,614 A	8/1994	Feiring	5,622,169 A	4/1997	Golden et al.
5,337,678 A	8/1994	Grout	5,622,170 A	4/1997	Schulz
5,341,807 A	8/1994	Nardella	5,622,184 A	4/1997	Ashby et al.
5,343,865 A	9/1994	Gardineer et al.	5,623,931 A	4/1997	Wung et al.
5,345,940 A	9/1994	Seward et al.	5,624,430 A	4/1997	Eton et al.
5,348,020 A	9/1994	Hutson	5,626,554 A	5/1997	Ryaby et al.
5,350,352 A	9/1994	Buchholtz et al.	5,626,870 A	5/1997	Monshipouri et al.
5,357,961 A	10/1994	Fields et al.	5,630,419 A	5/1997	Ranalletta
5,375,596 A	12/1994	Twiss et al.	5,644,612 A	7/1997	Moorman et al.
5,376,083 A	12/1994	Mische	5,645,065 A	7/1997	Shapiro et al.
5,377,678 A	1/1995	Dumoulin et al.	5,651,047 A	7/1997	Moorman et al.
5,385,053 A	1/1995	Wlodarczyk et al.	5,654,864 A	8/1997	Ritter et al.
5,391,199 A	2/1995	Ben-Haim	D383,968 S	9/1997	Bidwell et al.
5,394,876 A	3/1995	Ma	5,662,115 A	9/1997	Torp et al.
5,394,877 A	3/1995	Orr et al.	5,665,477 A	9/1997	Meathrel et al.
5,395,366 A	3/1995	D'Andrea et al.	5,666,473 A	9/1997	Wallace
5,398,683 A	3/1995	Edwards et al.	5,666,958 A	9/1997	Rothenberg et al.
5,398,691 A	3/1995	Martin et al.	5,668,888 A	9/1997	Doi et al.
5,405,366 A	4/1995	Fox et al.	5,669,383 A	9/1997	Johnson
5,411,485 A	5/1995	Tennican et al.	5,669,388 A	9/1997	Vilkomerson
5,413,107 A	5/1995	Oakley et al.	5,676,159 A	10/1997	Navis
5,422,478 A	6/1995	Wlodarczyk et al.	5,676,673 A	10/1997	Ferre et al.
5,425,367 A	6/1995	Shapiro et al.	5,691,898 A	11/1997	Rosenberg et al.
5,425,370 A	6/1995	Vilkomerson	5,694,945 A	12/1997	Ben-Haim
5,425,382 A	6/1995	Golden et al.	5,695,479 A	12/1997	Jagpal
5,427,114 A	6/1995	Colliver et al.	5,697,377 A	12/1997	Wittkampf
5,429,132 A	7/1995	Guy et al.	5,699,801 A	12/1997	Atalar et al.
5,429,617 A	7/1995	Hammersmark et al.	5,700,889 A	12/1997	Blair
5,431,641 A	7/1995	Grozinger et al.	5,713,362 A	2/1998	Vilkomerson
5,433,729 A	7/1995	Adams et al.	5,713,363 A	2/1998	Seward et al.
5,437,276 A	8/1995	Takada	5,713,946 A	2/1998	Ben-Haim
5,437,277 A	8/1995	Dumoulin et al.	5,715,817 A	2/1998	Stevens-Wright et al.
5,438,873 A	8/1995	Wlodarczyk et al.	5,716,389 A	2/1998	Walinsky et al.
5,443,066 A	8/1995	Dumoulin et al.	5,718,241 A	2/1998	Ben-Haim et al.
5,443,489 A	8/1995	Ben-Haim	D391,838 S	3/1998	Bidwell et al.
5,445,150 A	8/1995	Dumoulin et al.	5,722,412 A	3/1998	Pflugrath et al.
5,450,846 A	9/1995	Goldreyer	5,727,550 A	3/1998	Montecalvo
			5,727,552 A	3/1998	Ryan
			5,727,553 A	3/1998	Saad
			5,729,055 A	3/1998	Manning
			5,729,129 A	3/1998	Acker

(56)

References Cited

U.S. PATENT DOCUMENTS

5,729,584 A	3/1998	Moorman et al.	5,919,141 A	7/1999	Money et al.
5,730,129 A	3/1998	Darrow et al.	5,919,170 A	7/1999	Woessner
5,731,996 A	3/1998	Gilbert	5,928,145 A	7/1999	Ocali et al.
5,733,323 A	3/1998	Buck et al.	5,929,607 A	7/1999	Rosenberg et al.
5,738,096 A	4/1998	Ben-Haim	5,931,788 A	8/1999	Keen et al.
5,740,808 A	4/1998	Panescu et al.	5,931,818 A	8/1999	Werp et al.
5,742,394 A	4/1998	Hansen	5,941,858 A	8/1999	Johnson
5,744,953 A	4/1998	Hansen	5,941,889 A	8/1999	Cermak
5,748,767 A	5/1998	Raab	5,941,904 A	8/1999	Johnston et al.
5,749,835 A	5/1998	Glantz	5,944,022 A	8/1999	Nardella et al.
5,749,938 A	5/1998	Coombs	5,944,023 A	8/1999	Johnson et al.
5,751,785 A	5/1998	Moorman et al.	5,953,683 A	9/1999	Hansen et al.
5,752,513 A	5/1998	Acker et al.	5,957,857 A	9/1999	Hartley
5,758,650 A	6/1998	Miller et al.	5,961,923 A	10/1999	Nova et al.
5,762,064 A	6/1998	Polvani	5,967,978 A	10/1999	Littmann et al.
5,767,669 A	6/1998	Hansen et al.	5,967,980 A	10/1999	Ferre et al.
5,767,960 A	6/1998	Orman et al.	5,967,991 A	10/1999	Gardineer et al.
5,769,786 A	6/1998	Wiegel	5,969,722 A	10/1999	Palm
5,769,843 A	6/1998	Abela et al.	5,978,705 A	11/1999	KenKnight et al.
5,769,881 A	6/1998	Schroepel et al.	5,982,915 A	11/1999	Doi et al.
5,771,896 A	6/1998	Sliwa, Jr. et al.	5,983,126 A	11/1999	Wittkampf
5,775,322 A	7/1998	Silverstein et al.	5,984,908 A	11/1999	Davis et al.
5,775,332 A	7/1998	Goldman	5,991,693 A	11/1999	Zalewski
5,779,638 A	7/1998	Vesely et al.	5,997,473 A	12/1999	Taniguchi et al.
5,782,767 A	7/1998	Pretlow, III	5,997,481 A	12/1999	Adams et al.
5,785,657 A	7/1998	Breyer et al.	6,006,123 A	12/1999	Nguyen et al.
5,792,055 A	8/1998	McKinnon et al.	6,011,988 A	1/2000	Lynch et al.
5,795,297 A	8/1998	Daigle	6,014,473 A	1/2000	Hossack et al.
5,795,298 A	8/1998	Vesely et al.	6,014,580 A	1/2000	Blume et al.
5,795,632 A	8/1998	Buchalter	6,015,414 A	1/2000	Werp et al.
5,797,849 A	8/1998	Vesely et al.	6,017,496 A	1/2000	Nova et al.
5,800,352 A	9/1998	Ferre et al.	6,019,724 A	2/2000	Gronningsaeter et al.
5,800,410 A	9/1998	Gawreluk	6,019,725 A	2/2000	Vesely et al.
5,800,497 A	9/1998	Bakels et al.	6,023,638 A	2/2000	Swanson
5,803,089 A	9/1998	Ferre et al.	6,026,312 A	2/2000	Shemwell et al.
5,810,733 A	9/1998	Van Creveld et al.	6,031,765 A	2/2000	Lee et al.
5,816,245 A	10/1998	Manseur et al.	6,032,070 A	2/2000	Flock et al.
5,817,022 A	10/1998	Vesely	6,039,694 A	3/2000	Larson et al.
5,817,024 A	10/1998	Ogle et al.	6,050,718 A	4/2000	Schena et al.
5,820,549 A	10/1998	Marian, Jr.	6,052,610 A	4/2000	Koch
5,824,031 A	10/1998	Cookston et al.	6,052,618 A	4/2000	Dahlke et al.
5,829,444 A	11/1998	Ferre et al.	D424,693 S	5/2000	Pruter
5,830,145 A	11/1998	Tenhoff	6,059,718 A	5/2000	Taniguchi et al.
5,831,260 A	11/1998	Hansen	6,064,903 A	5/2000	Riechers et al.
5,833,608 A	11/1998	Acker	6,064,905 A	5/2000	Webster, Jr. et al.
5,833,622 A	11/1998	Meathrel et al.	6,066,094 A	5/2000	Ben-Haim
5,835,561 A	11/1998	Moorman et al.	6,068,599 A	5/2000	Saito et al.
5,836,882 A	11/1998	Frazin	6,073,043 A	6/2000	Schneider
5,836,990 A	11/1998	Li	6,074,367 A	6/2000	Hubbell
5,840,024 A	11/1998	Taniguchi et al.	6,075,442 A	6/2000	Welch
5,840,025 A	11/1998	Ben-Haim	6,076,007 A	6/2000	England et al.
5,840,030 A	11/1998	Ferek-Petric et al.	6,082,366 A	7/2000	Andra et al.
5,840,031 A	11/1998	Crowley	6,083,170 A	7/2000	Ben-Haim
5,842,986 A	12/1998	Avrin et al.	6,099,524 A	8/2000	Lipson et al.
5,843,076 A	12/1998	Webster, Jr. et al.	6,100,026 A	8/2000	Nova et al.
5,843,153 A	12/1998	Johnston et al.	6,102,044 A	8/2000	Naidyhorski
5,844,140 A	12/1998	Seale	6,107,699 A	8/2000	Swanson
5,846,198 A	12/1998	Killmann	6,112,111 A	8/2000	Glantz
5,855,553 A	1/1999	Tajima et al.	6,113,504 A	9/2000	Kuesters
5,859,893 A	1/1999	Moorman et al.	6,115,624 A	9/2000	Lewis et al.
5,865,748 A	2/1999	Co et al.	6,120,445 A	9/2000	Grunwald
5,868,673 A	2/1999	Vesely	6,128,174 A	10/2000	Ritter et al.
5,873,822 A	2/1999	Ferre et al.	6,129,668 A	10/2000	Haynor et al.
5,876,328 A	3/1999	Fox et al.	6,132,378 A	10/2000	Marino
5,879,297 A	3/1999	Haynor et al.	6,132,379 A	10/2000	Patacsil et al.
5,893,363 A	4/1999	Little et al.	6,135,961 A	10/2000	Pflugrath et al.
5,897,495 A	4/1999	Aida et al.	6,136,274 A	10/2000	Nova et al.
5,899,860 A	5/1999	Pfeiffer et al.	6,138,681 A	10/2000	Chen et al.
5,902,238 A	5/1999	Golden et al.	6,139,496 A	10/2000	Chen et al.
5,907,487 A	5/1999	Rosenberg et al.	6,139,502 A	10/2000	Fredriksen
5,908,385 A	6/1999	Chechelski et al.	6,144,300 A	11/2000	Dames et al.
5,910,113 A	6/1999	Pruter	6,148,823 A	11/2000	Hastings
5,910,120 A	6/1999	Kim et al.	6,152,933 A	11/2000	Werp et al.
5,913,820 A	6/1999	Bladen et al.	6,157,853 A	12/2000	Blume et al.
5,913,830 A	6/1999	Miles	6,165,144 A	12/2000	Talish et al.
			6,166,496 A	12/2000	Lys et al.
			6,166,806 A	12/2000	Tjin
			6,167,765 B1	1/2001	Weitzel
			6,172,499 B1	1/2001	Ashe

(56)

References Cited

U.S. PATENT DOCUMENTS

6,173,199	B1	1/2001	Gabriel	6,364,823	B1	4/2002	Garibaldi et al.
6,173,715	B1	1/2001	Sinanan et al.	6,364,839	B1	4/2002	Little et al.
6,175,756	B1	1/2001	Ferre et al.	6,366,804	B1	4/2002	Mejia
6,176,829	B1	1/2001	Vilkomerson	6,368,285	B1	4/2002	Osadchy et al.
6,193,743	B1	2/2001	Brayton et al.	6,370,411	B1	4/2002	Osadchy et al.
6,200,305	B1	3/2001	Berthiaume et al.	6,373,240	B1	4/2002	Govari
6,203,499	B1	3/2001	Imling et al.	6,373,388	B1	4/2002	Dames et al.
6,206,843	B1	3/2001	Iger et al.	6,374,134	B1	4/2002	Bladen et al.
6,208,884	B1	3/2001	Kumar et al.	6,374,670	B1	4/2002	Spelman et al.
6,211,626	B1	4/2001	Lys et al.	6,375,606	B1	4/2002	Garibaldi et al.
6,211,666	B1	4/2001	Acker	6,375,639	B1	4/2002	Duplessie et al.
6,212,426	B1	4/2001	Swanson	6,377,857	B1	4/2002	Brayton et al.
6,216,027	B1	4/2001	Willis et al.	6,379,302	B1	4/2002	Kessman et al.
6,216,028	B1	4/2001	Haynor et al.	6,379,303	B1	4/2002	Seitz et al.
6,216,029	B1	4/2001	Paltiel	6,379,307	B1	4/2002	Filly et al.
6,223,087	B1	4/2001	Williams	6,381,485	B1	4/2002	Hunter et al.
6,226,547	B1	5/2001	Lockhart et al.	6,385,472	B1	5/2002	Hall et al.
6,230,046	B1	5/2001	Crane et al.	6,385,476	B1	5/2002	Osadchy et al.
6,233,476	B1	5/2001	Strommer et al.	6,398,736	B1	6/2002	Seward
6,233,479	B1	5/2001	Haddad et al.	6,401,723	B1	6/2002	Garibaldi et al.
6,238,344	B1	5/2001	Gamelsky et al.	6,406,442	B1	6/2002	McFann et al.
6,241,673	B1	6/2001	Williams	6,412,978	B1	7/2002	Watanabe et al.
6,246,231	B1	6/2001	Ashe	6,412,980	B1	7/2002	Lounsberry et al.
6,246,898	B1	6/2001	Vesely et al.	6,417,839	B1	7/2002	Odell
6,248,072	B1	6/2001	Murkin	6,418,332	B1	7/2002	Mastrototaro et al.
6,248,074	B1	6/2001	Ohno et al.	6,418,335	B2	7/2002	Avrin et al.
6,248,075	B1	6/2001	McGee et al.	6,423,002	B1	7/2002	Hossack
6,253,770	B1	7/2001	Acker et al.	6,423,050	B1	7/2002	Twardowski
6,259,941	B1	7/2001	Chia et al.	6,427,079	B1	7/2002	Schneider et al.
6,261,231	B1	7/2001	Damphousse et al.	6,428,551	B1	8/2002	Hall et al.
6,263,230	B1	7/2001	Haynor et al.	6,430,315	B1	8/2002	Makram-Ebeid
6,266,550	B1	7/2001	Selmon et al.	6,432,069	B1	8/2002	Godo et al.
6,266,551	B1	7/2001	Osadchy et al.	6,438,411	B1	8/2002	Guttman et al.
6,266,552	B1	7/2001	Slettenmark	6,442,416	B1	8/2002	Schultz
6,266,563	B1	7/2001	KenKnight et al.	6,443,907	B1	9/2002	Mansy et al.
6,271,833	B1	8/2001	Rosenberg et al.	6,445,943	B1	9/2002	Ferre et al.
6,272,371	B1	8/2001	Shlomo	6,459,919	B1	10/2002	Lys et al.
6,272,374	B1	8/2001	Flock et al.	6,463,121	B1	10/2002	Milnes
6,275,258	B1	8/2001	Chim	6,473,167	B1	10/2002	Odell
6,275,724	B1	8/2001	Dickinson et al.	6,474,341	B1	11/2002	Hunter et al.
6,277,077	B1	8/2001	Brisken et al.	6,475,152	B1	11/2002	Kelly, Jr. et al.
6,284,459	B1	9/2001	Nova et al.	6,475,223	B1	11/2002	Werp et al.
6,285,898	B1	9/2001	Ben-Haim	6,477,402	B1	11/2002	Lynch et al.
6,288,704	B1	9/2001	Flack et al.	6,484,118	B1	11/2002	Govari et al.
6,292,678	B1	9/2001	Hall et al.	6,487,916	B1	12/2002	Gomm et al.
6,292,680	B1	9/2001	Somogyi et al.	6,491,671	B1	12/2002	Larson, III et al.
6,292,901	B1	9/2001	Lys et al.	6,493,573	B1	12/2002	Martinelli et al.
6,293,955	B1	9/2001	Houser et al.	6,496,715	B1	12/2002	Lee et al.
6,296,604	B1	10/2001	Garibaldi et al.	6,498,944	B1	12/2002	Ben-Haim et al.
6,298,261	B1	10/2001	Rex	6,500,141	B1	12/2002	Irion et al.
6,304,768	B1	10/2001	Blume et al.	6,505,062	B1	1/2003	Ritter et al.
6,306,097	B1	10/2001	Park et al.	6,507,751	B2	1/2003	Blume et al.
6,311,082	B1	10/2001	Creighton, IV et al.	6,508,802	B1	1/2003	Rosengart et al.
6,315,709	B1	11/2001	Garibaldi et al.	6,512,958	B1	1/2003	Swoyer et al.
6,315,727	B1	11/2001	Coleman et al.	6,514,249	B1	2/2003	Maguire et al.
6,319,668	B1	11/2001	Nova et al.	6,515,657	B1	2/2003	Zanelli
6,323,769	B1	11/2001	Dames et al.	6,516,212	B1	2/2003	Bladen et al.
6,323,770	B1	11/2001	Dames et al.	6,516,231	B1	2/2003	Flammang
6,324,416	B1	11/2001	Seibert	6,516,807	B1	2/2003	Panescu et al.
6,325,540	B1	12/2001	Lounsberry et al.	6,517,520	B2	2/2003	Chang et al.
6,325,762	B1	12/2001	Tjin	6,522,906	B1	2/2003	Salisbury, Jr. et al.
6,329,139	B1	12/2001	Nova et al.	6,522,907	B1	2/2003	Bladen et al.
6,329,916	B1	12/2001	Dames et al.	6,522,909	B1	2/2003	Garibaldi et al.
6,330,467	B1	12/2001	Creighton, IV et al.	6,524,303	B1	2/2003	Garibaldi
6,332,089	B1	12/2001	Acker et al.	6,528,954	B1	3/2003	Lys et al.
6,332,874	B1	12/2001	Eliassen et al.	6,528,991	B2	3/2003	Ashe
6,340,588	B1	1/2002	Nova et al.	6,529,761	B2	3/2003	Creighton, IV et al.
6,340,868	B1	1/2002	Lys et al.	6,534,982	B1	3/2003	Jakab
6,341,231	B1	1/2002	Ferre et al.	6,535,625	B1	3/2003	Chang et al.
6,346,081	B1	2/2002	Vilkomerson	6,537,192	B1	3/2003	Elliot et al.
6,348,911	B1	2/2002	Rosenberg et al.	6,537,196	B1	3/2003	Creighton, IV et al.
6,350,160	B1	2/2002	Feuersanger et al.	6,538,634	B1	3/2003	Chui et al.
6,352,363	B1	3/2002	Munger et al.	6,540,699	B1	4/2003	Smith
6,355,026	B1	3/2002	Mick	6,542,766	B2	4/2003	Hall et al.
6,361,499	B1	3/2002	Bates et al.	6,544,251	B1	4/2003	Crawford
				6,546,270	B1	4/2003	Goldin et al.
				6,546,279	B1	4/2003	Bova et al.
				6,546,787	B1	4/2003	Schiller et al.
				6,549,794	B1	4/2003	Nadeau, Jr. et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

6,552,841	B1	4/2003	Lasser et al.	6,799,066	B2	9/2004	Steines et al.
6,556,858	B1	4/2003	Zeman	6,815,651	B2	11/2004	Odell
6,562,019	B1	5/2003	Sell	6,816,266	B2	11/2004	Varshneya et al.
6,564,087	B1	5/2003	Pitris et al.	6,817,364	B2	11/2004	Garibaldi
6,569,101	B2	5/2003	Quistgaard et al.	6,832,199	B1	12/2004	Kucek et al.
6,571,004	B1	5/2003	Florent et al.	6,834,201	B2	12/2004	Gillies et al.
6,574,518	B1	6/2003	Lounsberry et al.	6,844,713	B2	1/2005	Steber et al.
6,575,908	B2	6/2003	Barnes et al.	6,845,142	B2	1/2005	Ohishi
6,577,080	B2	6/2003	Lys et al.	6,856,823	B2	2/2005	Ashe
6,577,896	B2	6/2003	Werner et al.	6,860,422	B2	3/2005	Hull et al.
6,584,343	B1	6/2003	Ransbury et al.	6,862,467	B2	3/2005	Moore et al.
6,593,754	B1	7/2003	Steber et al.	6,869,390	B2	3/2005	Elliott et al.
6,593,884	B1	7/2003	Gilboa et al.	6,875,179	B2	4/2005	Ferguson et al.
6,596,791	B2	7/2003	Santar et al.	6,879,160	B2	4/2005	Jakab
6,597,943	B2	7/2003	Taha et al.	6,889,091	B2	5/2005	Hine et al.
6,599,249	B1	7/2003	Nordgren et al.	6,895,268	B1	5/2005	Rahn et al.
6,607,488	B1	8/2003	Jackson et al.	6,902,528	B1	6/2005	Garibaldi et al.
6,610,058	B2	8/2003	Flores	6,908,433	B1	6/2005	Pruter
6,611,141	B1	8/2003	Schulz et al.	6,911,026	B1	6/2005	Hall et al.
6,615,071	B1	9/2003	Casscells, III et al.	6,923,782	B2	8/2005	O'Mahony et al.
6,615,155	B2	9/2003	Gilboa	6,926,673	B2	8/2005	Roberts et al.
6,618,612	B1	9/2003	Acker et al.	6,934,575	B2	8/2005	Ferre et al.
6,626,832	B1	9/2003	Paltiel et al.	6,936,010	B2	8/2005	Fang et al.
6,626,834	B2	9/2003	Dunne et al.	6,940,379	B2	9/2005	Creighton
6,626,902	B1	9/2003	Kucharczyk et al.	6,941,166	B2	9/2005	MacAdam et al.
6,630,879	B1	10/2003	Creighton, IV et al.	6,947,788	B2	9/2005	Gilboa et al.
6,635,027	B1	10/2003	Cragg et al.	6,950,689	B1	9/2005	Willis et al.
6,645,148	B2	11/2003	Nguyen-Dinh et al.	6,953,754	B2	10/2005	Machida et al.
6,648,875	B2	11/2003	Simpson et al.	6,958,677	B1	10/2005	Carter
6,649,914	B1	11/2003	Moorman et al.	6,959,214	B2	10/2005	Pape et al.
6,652,506	B2	11/2003	Bowe et al.	6,962,566	B2	11/2005	Quistgaard et al.
6,662,034	B2	12/2003	Segner et al.	6,968,846	B2	11/2005	Viswanathan
6,672,308	B1	1/2004	Gaspari	6,975,197	B2	12/2005	Creighton, IV
6,677,752	B1	1/2004	Creighton, IV et al.	6,976,962	B2	12/2005	Bullis
6,679,857	B1	1/2004	Bastia et al.	6,976,987	B2	12/2005	Flores
6,684,176	B2	1/2004	Willins et al.	6,980,843	B2	12/2005	Eng et al.
6,685,644	B2	2/2004	Seo	6,980,852	B2	12/2005	Jersey-Willuhn et al.
6,687,531	B1	2/2004	Ferre et al.	6,980,921	B2	12/2005	Anderson et al.
6,689,119	B1	2/2004	Di Caprio et al.	6,986,739	B2	1/2006	Warren et al.
6,690,963	B2	2/2004	Ben-Haim et al.	6,999,821	B2	2/2006	Jenney et al.
6,690,964	B2	2/2004	Bieger et al.	7,001,355	B2	2/2006	Nunomura et al.
6,690,968	B2	2/2004	Mejia	7,008,418	B2	3/2006	Hall et al.
6,694,167	B1	2/2004	Ferre et al.	7,010,338	B2	3/2006	Ritter et al.
6,695,786	B2	2/2004	Wang et al.	7,015,393	B2	3/2006	Weiner et al.
6,701,179	B1	3/2004	Martinelli et al.	7,017,584	B2	3/2006	Garibaldi et al.
6,701,918	B2	3/2004	Fariss et al.	7,019,610	B2	3/2006	Creighton, IV et al.
6,702,804	B1	3/2004	Ritter et al.	7,020,512	B2	3/2006	Ritter et al.
6,704,590	B2	3/2004	Haldeman	D518,574	S	4/2006	Chaggares
6,709,390	B1	3/2004	Marie Pop	7,022,075	B2	4/2006	Grunwald et al.
6,711,429	B1	3/2004	Gilboa et al.	7,022,082	B2	4/2006	Sonek
6,711,431	B2	3/2004	Pratt et al.	7,026,927	B2	4/2006	Wright et al.
6,719,699	B2	4/2004	Smith	7,027,634	B2	4/2006	Odell
6,719,724	B1	4/2004	Walker et al.	7,028,387	B1	4/2006	Huynh et al.
6,719,756	B1	4/2004	Muntermann	7,029,446	B2	4/2006	Wendelken et al.
6,720,745	B2	4/2004	Lys et al.	7,033,603	B2	4/2006	Nelson et al.
6,733,511	B2	5/2004	Hall et al.	D520,139	S	5/2006	Chaggares
6,736,782	B2	5/2004	Pfeiffer et al.	D520,140	S	5/2006	Chaggares
6,738,656	B1	5/2004	Ferre et al.	7,038,398	B1	5/2006	Lys et al.
6,740,103	B2	5/2004	Werp et al.	7,038,657	B2	5/2006	Rosenberg et al.
6,743,177	B2	6/2004	Ito et al.	7,043,293	B1	5/2006	Baura
6,754,596	B2	6/2004	Ashe	7,054,228	B1	5/2006	Hickling
6,755,789	B2	6/2004	Stringer et al.	7,066,914	B2	6/2006	Andersen
6,755,816	B2	6/2004	Ritter et al.	7,066,924	B1	6/2006	Garibaldi et al.
6,757,557	B1	6/2004	Bladen et al.	D525,363	S	7/2006	Chaggares
6,763,261	B2	7/2004	Casscells, III et al.	7,070,565	B2	7/2006	Vaezy et al.
6,764,449	B2	7/2004	Lee et al.	7,072,704	B2	7/2006	Bucholz
6,768,496	B2	7/2004	Bieger et al.	7,082,325	B2	7/2006	Hashimshony et al.
6,772,001	B2	8/2004	Maschke et al.	7,090,639	B2	8/2006	Govari
6,774,624	B2	8/2004	Anderson et al.	7,096,148	B2	8/2006	Anderson et al.
6,783,536	B2	8/2004	Vilsmeier et al.	7,096,870	B2	8/2006	Lamprich et al.
6,784,660	B2	8/2004	Ashe	7,098,907	B2	8/2006	Houston et al.
6,785,571	B2	8/2004	Glossop et al.	7,103,205	B2	9/2006	Wang et al.
6,786,219	B2	9/2004	Garibaldi et al.	7,104,980	B1	9/2006	Laherty et al.
6,788,967	B2	9/2004	Ben-Haim et al.	7,106,043	B1	9/2006	Da Silva et al.
6,794,667	B2	9/2004	Noshi	7,106,431	B2	9/2006	Odell
				7,106,479	B2	9/2006	Roy et al.
				7,107,105	B2	9/2006	Bjorklund et al.
				7,132,804	B2	11/2006	Lys et al.
				7,137,976	B2	11/2006	Ritter et al.

(56)

References Cited

U.S. PATENT DOCUMENTS

7,141,812	B2	11/2006	Appleby et al.	7,751,865	B2	7/2010	Jacob et al.
7,142,905	B2	11/2006	Slayton et al.	7,766,839	B2	8/2010	Rogers et al.
7,148,970	B2	12/2006	de Boer	7,774,051	B2	8/2010	Voth
7,153,291	B2	12/2006	Bierman	7,794,407	B2	9/2010	Rothenberg
7,161,453	B2	1/2007	Creighton, IV	7,798,970	B2	9/2010	Lo et al.
7,162,291	B1	1/2007	Nachaliel	7,819,810	B2	10/2010	Stringer et al.
7,167,738	B2	1/2007	Schweikard et al.	D629,526	S	12/2010	Ladwig et al.
7,169,107	B2	1/2007	Jersey-Willuhn et al.	D629,527	S	12/2010	Crunkilton
7,174,201	B2	2/2007	Govari et al.	7,850,613	B2	12/2010	Stribling
7,175,646	B2	2/2007	Brenneman et al.	D630,756	S	1/2011	Kitayama
7,180,252	B2	2/2007	Lys et al.	D630,757	S	1/2011	Kitayama
7,184,820	B2	2/2007	Jersey-Willuhn et al.	7,909,815	B2	3/2011	Whitmore, III et al.
7,189,198	B2	3/2007	Harburn et al.	7,931,596	B2	4/2011	Rachlin et al.
7,190,819	B2	3/2007	Viswanathan	7,976,469	B2	7/2011	Bonde et al.
7,194,295	B2	3/2007	Vilsmeier	7,998,073	B2	8/2011	Roth et al.
7,204,798	B2	4/2007	Zdeblick et al.	8,118,743	B2	2/2012	Park et al.
7,206,064	B2	4/2007	Rogers et al.	8,388,541	B2	3/2013	Messerly et al.
7,207,941	B2	4/2007	Sharf	8,388,546	B2	3/2013	Rothenberg
7,211,082	B2	5/2007	Hall et al.	8,437,833	B2	5/2013	Silverstein
7,214,191	B2	5/2007	Stringer et al.	D684,265	S	6/2013	Cadera
7,215,326	B2	5/2007	Rosenberg	8,478,382	B2	7/2013	Burnside et al.
7,221,104	B2	5/2007	Lys et al.	8,512,256	B2	8/2013	Rothenberg
7,223,256	B2	5/2007	Bierman	8,801,693	B2	8/2014	He et al.
7,229,400	B2	6/2007	Elliott et al.	D724,745	S	3/2015	Orome et al.
7,231,243	B2	6/2007	Tearney et al.	2002/0019447	A1	2/2002	Renn et al.
7,236,157	B2	6/2007	Schena et al.	2002/0022777	A1	2/2002	Crieghton et al.
7,236,816	B2	6/2007	Kumar et al.	2002/0032391	A1	3/2002	McFann et al.
7,237,313	B2	7/2007	Skujins et al.	2002/0055680	A1	5/2002	Miele et al.
7,241,267	B2	7/2007	Furia	2002/0082559	A1	6/2002	Chang et al.
7,244,234	B2	7/2007	Ridley et al.	2002/0113555	A1	8/2002	Lys et al.
7,248,032	B1	7/2007	Hular et al.	2002/0114518	A1	8/2002	Wilt
7,248,914	B2	7/2007	Hastings et al.	2002/0123679	A1	9/2002	Dominguez
7,264,584	B2	9/2007	Ritter et al.	2002/0128554	A1	9/2002	Seward
7,270,662	B2	9/2007	Visram et al.	2002/0133079	A1	9/2002	Sandhu
7,275,682	B2	10/2007	Excoffier et al.	2002/0151789	A1	10/2002	Mansy et al.
7,276,044	B2	10/2007	Ferry et al.	2002/0156363	A1	10/2002	Hunter et al.
7,286,034	B2	10/2007	Creighton	2002/0156376	A1	10/2002	Wang et al.
7,291,146	B2	11/2007	Steinke et al.	2002/0165448	A1	11/2002	Ben-Haim et al.
7,297,140	B2	11/2007	Orlu et al.	2002/0165534	A1	11/2002	Hayzelden et al.
7,308,296	B2	12/2007	Lys et al.	2002/0198568	A1	12/2002	Hafer et al.
7,310,150	B2	12/2007	Guillermo et al.	2003/0002727	A1	1/2003	MacMahon
7,321,228	B2	1/2008	Govari	2003/0009132	A1	1/2003	Schwartz et al.
7,342,058	B2	3/2008	Peppmoller et al.	2003/0011359	A1	1/2003	Ashe
D566,284	S	4/2008	Kitayama et al.	2003/0013966	A1	1/2003	Barnes et al.
7,355,716	B2	4/2008	de Boer et al.	2003/0018276	A1	1/2003	Mansy et al.
7,360,427	B2	4/2008	Drinkwater et al.	2003/0036696	A1	2/2003	Willis et al.
7,366,376	B2	4/2008	Shishkov et al.	2003/0040671	A1	2/2003	Somogyi et al.
7,366,562	B2	4/2008	Dukeshner et al.	2003/0072805	A1	4/2003	Miyazawa et al.
7,366,563	B2	4/2008	Kleen et al.	2003/0076281	A1	4/2003	Morgan et al.
7,373,271	B1	5/2008	Schneider	2003/0083698	A1	5/2003	Whitehurst et al.
7,382,949	B2	6/2008	Bouma et al.	2003/0088195	A1	5/2003	Vardi et al.
7,418,169	B2	8/2008	Tearney et al.	2003/0100849	A1	5/2003	Jang
7,447,408	B2	11/2008	Bouma et al.	2003/0114742	A1	6/2003	Lewkowicz et al.
7,452,331	B1	11/2008	Pruter	2003/0114777	A1	6/2003	Griffin et al.
7,452,358	B2	11/2008	Stern et al.	2003/0120150	A1	6/2003	Govari
D585,556	S	1/2009	Kosaku	2003/0120154	A1	6/2003	Sauer et al.
7,479,141	B2	1/2009	Kleen et al.	2003/0139661	A1	7/2003	Kimchy et al.
7,534,223	B2	5/2009	Boutillette et al.	2003/0149328	A1	8/2003	Elliott et al.
7,538,859	B2	5/2009	Tearney et al.	2003/0149359	A1	8/2003	Smith
7,547,282	B2	6/2009	Lo et al.	2003/0152290	A1	8/2003	Odell
7,551,293	B2	6/2009	Yelin et al.	2003/0160721	A1	8/2003	Gilboa et al.
D599,909	S	9/2009	Rinott et al.	2003/0163037	A1	8/2003	Bladen et al.
D603,050	S	10/2009	Chen	2003/0171691	A1	9/2003	Casscells et al.
7,599,730	B2	10/2009	Hunter et al.	2003/0173953	A1	9/2003	Ashe
D603,520	S	11/2009	Ninomiya et al.	2003/0184544	A1	10/2003	Prudent
7,635,336	B1	12/2009	Pruter	2003/0191392	A1	10/2003	Haldeman
7,637,163	B2	12/2009	Fetzer et al.	2003/0191460	A1	10/2003	Hobbs et al.
7,640,053	B2	12/2009	Verin	2003/0195420	A1	10/2003	Mendlein et al.
7,651,469	B2	1/2010	Osborne et al.	2003/0199746	A1	10/2003	Fuimaono et al.
7,652,080	B2	1/2010	Peppmoller et al.	2003/0208142	A1	11/2003	Boudewijn et al.
D609,814	S	2/2010	Banryu	2003/0216639	A1	11/2003	Gilboa et al.
7,665,893	B2	2/2010	Buchalter	2003/0220557	A1	11/2003	Cleary et al.
7,668,583	B2	2/2010	Fegert et al.	2003/0220578	A1	11/2003	Ho et al.
7,699,782	B2	4/2010	Angelsen et al.	2003/0229298	A1	12/2003	Iwami et al.
7,727,192	B2	6/2010	Tokumoto et al.	2003/0233042	A1	12/2003	Ashe
				2004/0015070	A1	1/2004	Liang et al.
				2004/0024301	A1	2/2004	Hockett et al.
				2004/0030319	A1	2/2004	Korkor et al.
				2004/0043688	A1*	3/2004	Soerens et al. 442/149

(56)

References Cited

U.S. PATENT DOCUMENTS

2004/0054278 A1	3/2004	Kimchy et al.	2005/0222532 A1	10/2005	Bertolero et al.
2004/0082916 A1	4/2004	Jenkins	2005/0240102 A1	10/2005	Rachlin et al.
2004/0087877 A1	5/2004	Besz et al.	2005/0256398 A1	11/2005	Hastings et al.
2004/0088136 A1	5/2004	Ashe	2005/0256541 A1	11/2005	Stypulkowski
2004/0097803 A1	5/2004	Panescu	2006/0015003 A1	1/2006	Moaddes et al.
2004/0097804 A1	5/2004	Sobe	2006/0025677 A1	2/2006	Verard et al.
2004/0097805 A1	5/2004	Verard et al.	2006/0058633 A1	3/2006	Hoshino et al.
2004/0097806 A1	5/2004	Hunter et al.	2006/0068074 A1	3/2006	Stefandl
2004/0116809 A1	6/2004	Chow et al.	2006/0084867 A1	4/2006	Tremblay et al.
2004/0127805 A1	7/2004	MacAdam et al.	2006/0116571 A1	6/2006	Maschke et al.
2004/0131998 A1	7/2004	Marom et al.	2006/0116578 A1	6/2006	Grunwald et al.
2004/0133111 A1	7/2004	Szczeczek et al.	2006/0149134 A1	7/2006	Soper et al.
2004/0133130 A1	7/2004	Ferry et al.	2006/0173329 A1	8/2006	Irioka et al.
2004/0135069 A1	7/2004	Odell	2006/0173407 A1	8/2006	Shaughnessy et al.
2004/0138564 A1	7/2004	Hwang et al.	2006/0176242 A1	8/2006	Jaramaz et al.
2004/0138570 A1	7/2004	Nita et al.	2006/0184074 A1	8/2006	Vaezy et al.
2004/0147837 A1	7/2004	Macaulay et al.	2006/0188487 A1	8/2006	Thomas et al.
2004/0150963 A1	8/2004	Holmberg et al.	2006/0206037 A1	9/2006	Braxton
2004/0152972 A1	8/2004	Hunter	2006/0211944 A1	9/2006	Mauge et al.
2004/0155609 A1	8/2004	Lys et al.	2006/0224188 A1	10/2006	Libbus et al.
2004/0158140 A1	8/2004	Fuimaono et al.	2006/0247746 A1	11/2006	Danek et al.
2004/0171924 A1	9/2004	Mire et al.	2006/0264756 A1	11/2006	Lo et al.
2004/0176688 A1	9/2004	Haldeman	2006/0276867 A1	12/2006	Viswanathan
2004/0186461 A1	9/2004	DiMatteo	2007/0010753 A1	1/2007	MacAdam
2004/0199069 A1	10/2004	Connelly et al.	2007/0016007 A1	1/2007	Govari et al.
2004/0210289 A1	10/2004	Wang et al.	2007/0016013 A1	1/2007	Camus
2004/0230271 A1	11/2004	Wang et al.	2007/0016068 A1	1/2007	Grunwald et al.
2004/0231065 A1	11/2004	Daniel et al.	2007/0016069 A1	1/2007	Grunwald et al.
2004/0234453 A1	11/2004	Smith	2007/0016070 A1	1/2007	Grunwald et al.
2004/0253365 A1	12/2004	Warren et al.	2007/0016072 A1	1/2007	Grunwald et al.
2004/0254470 A1	12/2004	Drinkwater et al.	2007/0049822 A1	3/2007	Bunce et al.
2004/0260174 A1	12/2004	Keene	2007/0049846 A1	3/2007	Bown et al.
2004/0267086 A1	12/2004	Anstadt et al.	2007/0055141 A1	3/2007	Kruger et al.
2005/0004450 A1	1/2005	Ben-Haim et al.	2007/0055142 A1	3/2007	Webler
2005/0021019 A1	1/2005	Hashimshony et al.	2007/0060992 A1	3/2007	Pappone
2005/0033150 A1	2/2005	Takahashi et al.	2007/0062544 A1	3/2007	Rauk Bergstrom et al.
2005/0033177 A1	2/2005	Rogers et al.	2007/0073155 A1	3/2007	Park et al.
2005/0038355 A1	2/2005	Gellman et al.	2007/0087038 A1	4/2007	Richardson et al.
2005/0049486 A1	3/2005	Urquhart et al.	2007/0093710 A1	4/2007	Maschke
2005/0049510 A1	3/2005	Haldeman et al.	2007/0100285 A1	5/2007	Griffin et al.
2005/0063194 A1	3/2005	Lys et al.	2007/0112282 A1	5/2007	Skujins et al.
2005/0070788 A1	3/2005	Wilson et al.	2007/0123769 A1	5/2007	Fuller et al.
2005/0075561 A1	4/2005	Golden	2007/0123805 A1	5/2007	Shireman et al.
2005/0085716 A1	4/2005	Hamm et al.	2007/0129770 A1	6/2007	Younis
2005/0085718 A1	4/2005	Shahidi	2007/0135803 A1	6/2007	Belson
2005/0085720 A1	4/2005	Jacob et al.	2007/0135886 A1	6/2007	Maschke
2005/0101868 A1	5/2005	Ridley et al.	2007/0156205 A1	7/2007	Larson et al.
2005/0101869 A1	5/2005	Burba et al.	2007/0161915 A1	7/2007	Desai
2005/0105081 A1	5/2005	Odell	2007/0167738 A1	7/2007	Timinger et al.
2005/0105101 A1	5/2005	Duling et al.	2007/0167801 A1	7/2007	Webler et al.
2005/0112135 A1	5/2005	Cormier et al.	2007/0167817 A1	7/2007	Huang et al.
2005/0113669 A1	5/2005	Helfer et al.	2007/0167997 A1	7/2007	Forsberg et al.
2005/0113676 A1	5/2005	Weiner et al.	2007/0197905 A1	8/2007	Timinger et al.
2005/0113700 A1	5/2005	Yanagihara et al.	2007/0208255 A1	9/2007	Ridley et al.
2005/0113873 A1	5/2005	Weiner et al.	2007/0225589 A1	9/2007	Viswanathan
2005/0113874 A1	5/2005	Connelly et al.	2007/0225610 A1	9/2007	Mickley et al.
2005/0113876 A1	5/2005	Weiner et al.	2007/0232882 A1	10/2007	Glossop et al.
2005/0131291 A1	6/2005	Floyd et al.	2007/0238984 A1	10/2007	Maschke et al.
2005/0149002 A1	7/2005	Wang et al.	2007/0239018 A1	10/2007	Fetzer et al.
2005/0151489 A1	7/2005	Lys et al.	2007/0244413 A1	10/2007	Biggins
2005/0154308 A1	7/2005	Quistgaard et al.	2007/0247454 A1	10/2007	Rahn et al.
2005/0159644 A1	7/2005	Takano	2007/0249911 A1	10/2007	Simon
2005/0159790 A1	7/2005	Shalev	2007/0265526 A1	11/2007	Govari et al.
2005/0165301 A1	7/2005	Smith et al.	2007/0280974 A1	12/2007	Son et al.
2005/0165313 A1	7/2005	Byron et al.	2007/0282196 A1	12/2007	Birk et al.
2005/0175665 A1	8/2005	Hunter et al.	2007/0282197 A1	12/2007	Bill et al.
2005/0175703 A1	8/2005	Hunter et al.	2007/0299352 A1	12/2007	Harlev et al.
2005/0178395 A1	8/2005	Hunter et al.	2008/0008745 A1	1/2008	Stinchcomb et al.
2005/0178396 A1	8/2005	Hunter et al.	2008/0009720 A1	1/2008	Schefelker et al.
2005/0182295 A1	8/2005	Soper et al.	2008/0015442 A1	1/2008	Watson et al.
2005/0203368 A1	9/2005	Verin	2008/0027320 A1	1/2008	Bolorforosh et al.
2005/0203396 A1	9/2005	Angelsen et al.	2008/0045908 A1	2/2008	Gould et al.
2005/0205081 A1	9/2005	Barker et al.	2008/0051626 A1	2/2008	Sato et al.
2005/0215901 A1	9/2005	Anderson et al.	2008/0081958 A1	4/2008	Denison et al.
2005/0215945 A1	9/2005	Harris et al.	2008/0082136 A1	4/2008	Gaudiani
			2008/0097232 A1	4/2008	Rothenberg
			2008/0108949 A1	5/2008	Beasley et al.
			2008/0114095 A1	5/2008	Peppmoller et al.
			2008/0114370 A1	5/2008	Schoenefeld

(56)

References Cited

U.S. PATENT DOCUMENTS

2008/0125772 A1 5/2008 Stone et al.
 2008/0139944 A1 6/2008 Weymer et al.
 2008/0146939 A1 6/2008 McMorrow et al.
 2008/0146940 A1 6/2008 Jenkins et al.
 2008/0152204 A1 6/2008 Huo et al.
 2008/0154100 A1 6/2008 Thalmeier et al.
 2008/0166453 A1 7/2008 Steele et al.
 2008/0171934 A1 7/2008 Greenan et al.
 2008/0183075 A1 7/2008 Govari et al.
 2008/0200754 A1 8/2008 Buchalter
 2008/0228082 A1 9/2008 Scheirer et al.
 2008/0255404 A1 10/2008 Nogawa et al.
 2008/0255475 A1 10/2008 Kondrosky et al.
 2008/0275765 A1 11/2008 Kuchar
 2009/0005675 A1 1/2009 Grunwald et al.
 2009/0018497 A1 1/2009 Birchard et al.
 2009/0018574 A1 1/2009 Martin
 2009/0024018 A1 1/2009 Boyden et al.
 2009/0036774 A1 2/2009 Weng et al.
 2009/0036790 A1 2/2009 Landesberg et al.
 2009/0043205 A1 2/2009 Pelissier et al.
 2009/0076327 A1 3/2009 Ohki
 2009/0082661 A1 3/2009 Saladin et al.
 2009/0084382 A1 4/2009 Jalde et al.
 2009/0101577 A1 4/2009 Fulkerson et al.
 2009/0118612 A1 5/2009 Grunwald et al.
 2009/0118706 A1 5/2009 Schweikert et al.
 2009/0124901 A1 5/2009 Fink et al.
 2009/0136099 A1 5/2009 Boyden et al.
 2009/0143736 A1 6/2009 Mittermeyer et al.
 2009/0149748 A1 6/2009 Lenhardt et al.
 2009/0156926 A1 6/2009 Messerly et al.
 2009/0163810 A1 6/2009 Kanade et al.
 2009/0171217 A1 7/2009 Kim et al.
 2009/0177083 A1 7/2009 Matsumura
 2009/0177090 A1 7/2009 Grunwald et al.
 2009/0177092 A1 7/2009 Riechers et al.
 2009/0203989 A1 8/2009 Burnside et al.
 2009/0204113 A1 8/2009 Macadam et al.
 2009/0209950 A1 8/2009 Starksen
 2009/0227952 A1 9/2009 Blakstvedt et al.
 2009/0234328 A1 9/2009 Cox et al.
 2009/0258171 A1 10/2009 Uang
 2009/0259124 A1 10/2009 Rothenberg
 2009/0262982 A1 10/2009 Markowitz et al.
 2009/0275828 A1 11/2009 Shachar et al.
 2009/0297441 A1 12/2009 Canham et al.
 2010/0004543 A1 1/2010 Ahlund et al.
 2010/0004547 A1 1/2010 Scholz et al.
 2010/0016726 A1 1/2010 Meier
 2010/0036227 A1 2/2010 Cox et al.
 2010/0049062 A1 2/2010 Ziv
 2010/0055153 A1 3/2010 Majmudar
 2010/0055184 A1 3/2010 Zeitels et al.
 2010/0057157 A1 3/2010 Govari et al.
 2010/0060472 A1 3/2010 Kimura et al.
 2010/0083719 A1 4/2010 Peppmoller et al.
 2010/0094116 A1 4/2010 Silverstein
 2010/0106011 A1 4/2010 Byrd et al.
 2010/0114573 A1 5/2010 Huang et al.
 2010/0126149 A1 5/2010 Kondou
 2010/0143119 A1 6/2010 Kooijman et al.
 2010/0179429 A1 7/2010 Ho et al.
 2010/0185097 A1 7/2010 Hall
 2010/0198048 A1 8/2010 Togawa
 2010/0204569 A1 8/2010 Burnside et al.
 2010/0217116 A1 8/2010 Eck et al.
 2010/0222663 A1 9/2010 Wilder et al.
 2010/0222664 A1 9/2010 Lemon et al.
 2010/0234733 A1 9/2010 Wahlheim
 2010/0249598 A1 9/2010 Smith et al.
 2010/0258033 A1 10/2010 Yang et al.
 2010/0273895 A1 10/2010 Stinchcomb et al.
 2010/0298702 A1 11/2010 Rogers et al.
 2010/0317981 A1 12/2010 Grunwald

2010/0318026 A1 12/2010 Grunwald
 2010/0331712 A1 12/2010 Rothenberg
 2011/0015527 A1 1/2011 Heasty et al.
 2011/0015533 A1 1/2011 Cox et al.
 2011/0040187 A1 2/2011 Matsumura
 2011/0040212 A1 2/2011 Dietz et al.
 2011/0052694 A1 3/2011 Stinchcomb et al.
 2011/0060215 A1 3/2011 Tupin, Jr. et al.
 2011/0087107 A1 4/2011 Lindekugel et al.
 2011/0087117 A1 4/2011 Tremper et al.
 2011/0171286 A1 7/2011 Cecile et al.
 2011/0196248 A1 8/2011 Grunwald
 2011/0278500 A1 * 11/2011 Bergeron 252/194
 2011/0282188 A1 11/2011 Burnside et al.
 2011/0295108 A1 12/2011 Cox et al.
 2011/0313293 A1 12/2011 Lindekugel et al.
 2012/0046562 A1 2/2012 Powers et al.
 2012/0059270 A1 3/2012 Grunwald
 2012/0095319 A1 4/2012 Kondrosky et al.
 2012/0108950 A1 5/2012 He et al.
 2012/0143029 A1 6/2012 Silverstein et al.
 2012/0165679 A1 6/2012 Orome et al.
 2012/0220854 A1 8/2012 Messerly et al.
 2013/0006102 A1 1/2013 Wilkes et al.
 2013/0060116 A1 3/2013 Messerly et al.
 2013/0123597 A1 5/2013 Rothenberg
 2014/0180116 A1 6/2014 Lindekugel et al.

FOREIGN PATENT DOCUMENTS

AU 20009592 9/2000
 AU 20015250 6/2001
 AU 768362 B2 12/2003
 AU 2001229024 B2 9/2005
 AU 2001283703 B2 5/2006
 AU 2006202149 6/2006
 AU 2006904933 9/2006
 AU 2006283022 B2 2/2012
 CA 2420676 2/2002
 CN 1672649 A 9/2005
 CN 102209490 A 10/2011
 CN 102802514 A 11/2012
 CN 102821679 A 12/2012
 CN 103037761 A 4/2013
 CN 103037762 A 4/2013
 CN 103118591 A 5/2013
 CN 103228219 A 7/2013
 DE 4319033 C1 6/1994
 EP 0359697 3/1990
 EP 0362821 4/1990
 EP 0399536 A1 11/1990
 EP 0823261 A2 2/1998
 EP 0928976 A2 7/1999
 EP 1311226 A1 5/2003
 EP 1504713 A1 2/2005
 EP 2313143 A1 4/2011
 EP 2440122 A1 4/2012
 EP 2464407 A2 6/2012
 EP 2482719 A1 8/2012
 EP 2575610 A1 4/2013
 EP 2575611 A1 4/2013
 EP 2603145 A2 6/2013
 EP 2605699 A2 6/2013
 FR 2545349 11/1984
 JP 01097440 4/1989
 JP 03173542 A 7/1991
 JP 4090741 8/1992
 JP 9-503054 3/1997
 JP 09-094298 A 4/1997
 JP 10043310 2/1998
 JP 10290839 A 11/1998
 JP 11128237 A 5/1999
 JP 2001161683 6/2001
 JP 2001340334 12/2001
 JP 2003501127 A 1/2003
 JP 2003061752 A 3/2003
 JP 2003299654 10/2003
 JP 2003334191 11/2003
 JP 2002520893 2/2004

(56)

References Cited

FOREIGN PATENT DOCUMENTS

JP	2004505748	T	2/2004
JP	2004515298	A	5/2004
JP	2006508744	A	3/2006
JP	5010604		6/2012
JP	2012-529929		11/2012
JP	2013-518676	A	5/2013
JP	2013-535301	A	9/2013
WO	9112836	A1	9/1991
WO	9203090		3/1992
WO	9403159	A1	2/1994
WO	9404938		3/1994
WO	9605768	A1	2/1996
WO	9607352	A1	3/1996
WO	9641119		12/1996
WO	9729683	A1	8/1997
WO	9743989	A1	11/1997
WO	9916495	A1	4/1999
WO	9949407	A1	9/1999
WO	0019906		4/2000
WO	0040155		7/2000
WO	0074775	A1	12/2000
WO	0176479	A1	10/2001
WO	0215973	A1	2/2002
WO	0225277	A1	3/2002
WO	03061752		7/2003
WO	03077759	A1	9/2003
WO	2004049970	A2	6/2004
WO	2005033524	A1	4/2005
WO	2005033574	A1	4/2005
WO	2005117690	A1	12/2005
WO	2006074509	A1	7/2006
WO	2006074510	A1	7/2006
WO	2006078677	A2	7/2006
WO	2006103661	A2	10/2006
WO	2006111056	A1	10/2006
WO	2007002541	A2	1/2007
WO	2007005976	A1	1/2007
WO	2007014447	A1	2/2007
WO	2007034196	A2	3/2007
WO	2007067324	A1	6/2007
WO	2007069168	A2	6/2007
WO	2007109123	A2	9/2007
WO	2007126536	A2	11/2007
WO	2007144894	A1	12/2007
WO	2008005480	A1	1/2008
WO	2008024596	A2	2/2008
WO	2008028253		3/2008
WO	2008083111		7/2008
WO	2008118992	A1	10/2008
WO	2008126074	A2	10/2008
WO	2008131017	A2	10/2008
WO	2008136008	A2	11/2008
WO	2009002514	A2	12/2008
WO	2009009064	A1	1/2009
WO	2009057774	A1	5/2009
WO	2009070616	A2	6/2009
WO	2009100158	A1	8/2009
WO	2009123819	A2	10/2009
WO	2009126340	A1	10/2009
WO	2009129475	A1	10/2009
WO	2009129477	A1	10/2009
WO	2009134605	A2	11/2009
WO	2009137262	A2	11/2009
WO	2010002313	A1	1/2010
WO	2010018500	A1	2/2010
WO	2010022370	A1	2/2010
WO	2010027349	A1	3/2010
WO	2010027471	A2	3/2010
WO	2010030820	A1	3/2010
WO	2010132857	A1	11/2010
WO	2010143196	A1	12/2010
WO	2010144922	A1	12/2010
WO	2011019760	A2	2/2011
WO	2011041450	A1	4/2011
WO	2011044421	A1	4/2011

WO	2011051406	A1	5/2011
WO	2011064209	A1	6/2011
WO	2011084593	A2	7/2011
WO	2011097312	A1	8/2011
WO	2011128052	A2	10/2011
WO	2011150358	A1	12/2011
WO	2012021542	A2	2/2012
WO	2012024577	A2	2/2012
WO	2012058461	A1	5/2012
WO	2012060562	A2	5/2012
WO	2012083245	A1	6/2012
WO	2012088535	A1	6/2012
WO	2013006817	A1	1/2013
WO	2013070775	A1	5/2013
WO	2013188833	A2	12/2013
WO	2014134171	A1	9/2014

OTHER PUBLICATIONS

PCT/US2012/063956 filed Nov. 7, 2012 International Search Report and Written Opinion dated Apr. 1, 2013.

PCT/US2009/056567 filed Sep. 10, 2009 International Preliminary Report on Patentability dated Mar. 15, 2011.

PCT/US2009/056567 filed Sep. 10, 2009 Search Report dated Nov. 6, 2009.

PCT/US2009/056567 filed Sep. 10, 2009 Written Opinion dated Nov. 6, 2009.

PCT/US2010/038555 filed Jun. 14, 2010 Search Report dated Oct. 5, 2010.

PCT/US2010/038555 filed Jun. 14, 2010 Written Opinion dated Oct. 5, 2010.

PCT/US2010/045084 filed Aug. 10, 2010 International Preliminary Report on Patentability dated Feb. 23, 2012.

PCT/US2010/045084 filed Aug. 10, 2010 Search Report dated Apr. 14, 2011.

PCT/US2010/045084 filed Aug. 10, 2010 Written Opinion dated Apr. 14, 2011.

PCT/US2010/050773 filed Sep. 29, 2010 Search Report dated Jan. 24, 2011.

PCT/US2010/050773 filed Sep. 29, 2010 Written Opinion dated Jan. 24, 2011.

PCT/US2010/051917 filed Oct. 8, 2010 Search Report dated Nov. 29, 2010.

PCT/US2010/051917 filed Oct. 8, 2010 Written Opinion dated Nov. 29, 2010.

PCT/US2011/023497 filed Feb. 2, 2011 Search Report dated Jun. 6, 2011.

PCT/US2011/023497 filed Feb. 2, 2011 Written Opinion dated Jun. 6, 2011.

PCT/US2011/038391 filed May 27, 2011 International Preliminary Report on Patentability and Written Opinion dated Dec. 4, 2012.

PCT/US2011/038391 filed May 27, 2011 International Search Report dated Sep. 21, 2011.

PCT/US2011/038415 filed May 27, 2011 International Preliminary Report on Patentability dated Dec. 13, 2012.

PCT/US2011/038415 filed May 27, 2011 International Search Report dated Sep. 28, 2011.

PCT/US2011/038415 filed May 27, 2011 Written Opinion dated Sep. 28, 2011.

PCT/US2011/047127 filed Aug. 9, 2011 International Preliminary Report on Patentability dated Apr. 18, 2013.

PCT/US2011/047127 filed Aug. 9, 2011 International Search Report dated Feb. 29, 2012.

PCT/US2011/047127 filed Aug. 9, 2011 Written Opinion dated Feb. 29, 2012.

PCT/US2011/048403 filed Aug. 19, 2011 International Search Report dated Dec. 15, 2011.

PCT/US2011/048403 filed Aug. 19, 2011 Written Opinion dated Dec. 15, 2011.

PCT/US2011/052793 filed Sep. 22, 2011 International Preliminary Report on Patentability dated Apr. 4, 2013.

PCT/US2011/052793 filed Sep. 22, 2011 International Search Report dated Jan. 6, 2012.

(56)

References Cited

OTHER PUBLICATIONS

- PCT/US2011/052793 filed Sep. 22, 2011 Written Opinion dated Jan. 6, 2012.
- PCT/US2011/058138 filed Oct. 27, 2011 International Preliminary Report on Patentability dated May 10, 2013.
- PCT/US2011/058138 filed Oct. 27, 2011 International Search Report dated Feb. 7, 2012.
- PCT/US2011/058138 filed Oct. 27, 2011 Written Opinion dated Feb. 7, 2012.
- PCT/US2011/067268 filed Dec. 23, 2011 International Preliminary Report on Patentability dated Jul. 4, 2013.
- PCT/US2011/067268 filed Dec. 23, 2011 International Search Report and Written Opinion dated Apr. 27, 2012.
- PCT/US2012/045814 filed Jul. 6, 2012 International Search Report and Written Opinion dated Oct. 1, 2012.
- Pennington, C.R., Right Atrial Thrombus: a Complication of Total Parenteral Nutrition, *British Medical Journal*, pp. 446-447, vol. 295, Aug. 15, 1987.
- Petersen, J et al, Silicone Venous Access Devices Positioned with their Tip High in the Superior Vena Cava are More Likely to Malfunction, *Am J Surg*, pp. 38-41, vol. 178 No. 1, Jul. 1999.
- Pittiruti, et al, Intracavitary EKG Monitoring: A reliable method for controlling tip position during and after PICC Insertion presentation in Catholic University, Rome, Italy in 2008.
- Pittiruti, et al. "The EKG Method for Positioning the Tip of PICCs: Results from Two Preliminary Studies." *JAVA*, vol. 13, No. 4, pp. 179-185, 2008.
- Polos, PG et al, Tips for Monitoring the Position of a Central Venous Catheter—How Placement can go awry—even when the anatomy is normal, *J Crit Illn*, pp. 660-674, vol. 8 No. 6, Jun. 1993 (Abstract only).
- Pop, Gheorghe A. et al., Catheter-based impedance measurements in the right atrium for continuously monitoring hematocrit and estimating blood viscosity changes; an in vivo feasibility study in swine, *Biosensors and Bioelectronics* 19 (2004) 1685-1693.
- Popp, M. B. et al., Accuracy of implanted port placement with the use of the electromagnetic CathTrack® catheter locator system, *The Journal of Vascular Access* 2005; 6: 9-12.
- Randolph AG et al, Ultrasound guidance for placement of central venous catheters: a meta-analysis of the literature, *Critical Care Medicine*, pp. 2053-2058, vol. 24, Dec. 1996.
- Reece, A et al, Positioning Long Lines: Contrast Versus Plain Radiography, *Arch Dis Child Fetal Neonatal Ed*, pp. 129-130, vol. 84 No. 2, Mar. 2001.
- Reynolds, N et al, Assessment of Distal Tip Position of Long Term Central Venous Feeding Catheters using Transesophageal Echocardiology, *JPEN J Parenter Enteral Nutr*, pp. 39-41, vol. 25 No. 1, Jan.-Feb. 2001.
- Ruschulte, Heiner et al, Prevention of Central Venous Catheter related infections with chlorhexidine gluconate impregnated wound dressings: A randomized controlled trial, presented as an abstract at the Annual meeting of the European Society of Anaesthesiologists (ESA) in Madrid, Spain in Jun. 2006, 12 pages, *Annals of Hematology*, Jul. 14, 2008.
- Rutherford, J. S. et al., Depth of Central Venous Catheterization: An Audit of Practice in a Cardiac Surgical Unit, *Anaesth Intens Care* 1994; 22: 267-271.
- Sacolick, et al. "Electromagnetically Tracked Placement of a Peripherally Inserted Central Catheter." *SPIE Medical Imaging*, 2004 Proceedings.
- Salem, et al. "A New Peripherally Implanted Subcutaneous Permanent Central Venous Access Device for Patients Requiring Chemotherapy." *Journal of Clinical Oncology*, vol. 11, No. 11, pp. 2181-2185, Nov. 1993.
- Savary, D et al, Intra-atrial Monitoring to Add Insertion of a Central Venous Line in Pre-Hospital Emergency Care *Journal Europeen des Urgences*, pp. 75-78, vol. 17 No. 2, 2004.
- Schafer et al. "Incorrect placement of a vena cava catheter and its prevention by intra-atrial ECG." *Anaesthesist*. Jan. 1988;37(1):49-51.
- Schummer, et al. "Central Venous Catheters—The inability of 'intra-atrial ECG' to prove adequate positioning." *British Journal of Anaesthesia*, vol. 93, No. 2, pp. 193-198, 2004.
- Kjelstrup T et al, Positioning of Central Venous Catheters using ECG, *Tidssk Nor Laegeforen*, pp. 599-601, vol. 111 No. 5, Feb. 1999 (Abstract only).
- Koffler, Julia, et al., Epinephrine application via an endotracheal airway and via the Combitube in esophageal position, *Critical Care Medicine*: May 2000, vol. 28: Issue 5, pp. 1445-1449.
- Konings, MK, et al., Development of an intravascular impedance catheter for detection of fatty lesions in arteries, *IEEE Trans Med Imaging* Aug. 1997; 16(4):439-46.
- Kowalski, CM et al, Migration of Central Venous Catheters: Implications for Initial Catheter Tip Positioning, *J Vasc Interv Radiol*, pp. 443-447, vol. 8 No. 3, May-Jun. 1997.
- Leowenthal, MR et al, The Peripherally Inserted Central Catheter (PICC): A Prospective Study of its Natural History after Fossa Insertion, *Anaesth Intensive Care*, pp. 21-24; vol. 30 No. 1, Feb. 2002.
- Lepage Ronan et al. ECG Segmentation and P-wave Feature Extraction: Application to Patients Prone to Atrial Fibrillation, *IEEE/EMBS Proceedings, 23rd Annual Conference, Istanbul, Turkey*, Oct. 25-28, 2001.
- Liu, Ji-Bin et al, Catheter-Based Intraluminal Sonography, *J Ultrasound Med*, pp. 145-160, vol. 23, 2004.
- Lucey, B et al, Routine Chest Radiographs after Central Line Insertion: Mandatory Postprocedural Evaluation or Unnecessary Waste of Resources?, *Cardiovasc Intervent Radiol*, pp. 381-384, vol. 22 No. 5, Sep.-Oct. 1999.
- Lum, Phillip, A New Formula-Based Measurement Guide for Optimal Positioning of Central Venous Catheters, *JAVA*, vol. 9, No. 2, pp. 80-85, 2004.
- Lynch, RE et al, A Procedure for Placing Pediatric Femoral Venous Catheter Tips near the Right Atrium, *Pediatr Emerg Care*, pp. 130-132, vol. 18 No. 2, Apr. 2002.
- Madan, et al. "Right Atrial Electrocardiography: A Technique for the Placement of Central Venous Catheters for Chemotherapy or Intravenous Nutrition." *British Journal of Surgery*, vol. B1, pp. 1604-1605, 1994.
- Madias, John E, Intracardiac (Superior Vena Cava/Right Atrial) ECGs using Saline Solution as the Conductive Medium for the Proper Positioning of the Shiley Hemodialysis Catheter: Is it Not Time to Forego the Postinsertion Chest Radiograph?, pp. 2363-2367, *CHEST*, 2003.
- Markovich, Mary B., Central Venous Catheter Tip Placement: Determination of Posterior Malposition-A Case Study, *JAVA*, vol. 11, No. 2, pp. 85-89, 2006.
- Martin, Roy W, An Ultrasound Catheter for Intravascular Measurement of Blood Flow: Technical Details, *IEEE Transactions on Sonics and Ultrasonics*, vol. SU-27, No. 6, pp. 277-286, Nov. 1980.
- McDonnell, "Intra-Atrial Electrocardiography (ECG) for Catheter Placement." Literature review prepared for Bard Access Systems, Oct. 2007.
- McGee et al., "Accurate Placement of Central Venous Catheters: A Prospective, Randomize, Multicenter Trial." *Critical Care Medicine*, vol. 21 No. 8, Aug. 1993.
- MedGraphics, CardioPerfect® Resting/Stress ECG System, 3 pages, 2001.
- Michenfelder, John et al, Air Embolism During Neurosurgery—An Evaluation of Right-Atrial Catheters for Diagnosis and Treatment, *JAMA*, pp. 1353-1358, vol. 208, No. 8, May 26, 1969.
- Michenfelder, John et al, Air Embolism During Neurosurgery. A New Method of Treatment, *Anesthesia and Analgesia*. Current Researches, pp. 390-395, vol. 45, No. 4, Jul.-Aug. 1966.
- MICROBIRD™ Miniaturized DC Magnetic Sensors for Intra-body Navigation and Localization, Specifications, 2005.
- MICRONIX CathRite™ Cardiac Access Device Brochure. Jun. 2004.
- Micronix Pty Ltd "CathRite" Guiding Styled Core Manufacturing, Jun. 15, 2006.
- Murthy, Vrudhula et al, Analysis of Power Spectral Densities of Electrocardiograms, *Mathematical Biosciences*, pp. 41-51, vol. 12 No. 1-2, Oct. 1971.

(56)

References Cited

OTHER PUBLICATIONS

- Nadroo, AM et al, Changes in Upper Extremity Position Cause Migration of Peripherally Inserted Central Catheters in Neonates, *Pediatrics*, pp. 131-136, vol. 110, Jul. 2002.
- Nakatani, K et al, Accurate Placement of Central Venous Catheters—ECG-guided method vs Patient Height Method, *Masui*, pp. 34-38, vol. 51 No. 1, Jan. 2002.
- Nazarian, GK et al, Changes in Tunneled Catheter Tip Position when a patient is Upright, *J Vasc Interv Radiol*, pp. 437-441, vol. 8 No. 3, May-Jun. 1997.
- Neurometer® CPT, Clinical Applications. Neurotron, Inc. website: www.neurotron.com/CLINAPS.html, last accessed Oct. 23, 2006.
- Neurometer® CPT, Frequently Asked Questions. Neurotron, Inc. website: www.neurotron.com/CPTFAQ/html, last accessed Oct. 23, 2006.
- Neurometer® CPT, Products Page. Neurotron, Inc. website: www.neurotron.com/products.html, last accessed Oct. 23, 2006.
- Neurometer® Electrodiagnostic Neuroselective Sensory Nerve Evaluation: Charts, Tables, Documents & Downloads. Neurotron, Inc. website: www.neurotron.com/downloads.html, last accessed Oct. 23, 2006.
- Odd, De et al, Does Radio-opaque Contrast Improve Radiographic localisation of Percutaneous Central Venous Lines?, *Arch Dis Child Fetal Neonatal Ed*, pp. 41-43, vol. 89 No. 1, Jan. 2004.
- Palesty, JA et al, Routine Chest Radiographs Following Central Venous Recatheterization over a Wire are not Justified, *Am J Surg*, pp. 618-621, vol. 176 No. 6, Dec. 1998.
- Paliotti, Roberta P. et al, Intravascular Doppler Technique for Monitoring Renal Venous Blood Flow in Man, *J Nephrol*, pp. 57-62, 2003.
- Parker, K.H. et al, Cardiovascular Fluid Dynamics, Department of Bioengineering, National Heart and Lung Institute, Imperial College of Science, Technology and Medicine, Cardiovascular Haemodynamics, pp. 1-28, Sep. 26, 2005.
- Pawlik, et al., "Central Venous Catheter Placement: Comparison of the Intravascular Guidewire and the Fluid Column Electrocardiograms." *European Journal of Anaesthesiology*, vol. 41, pp. 594-599, 2004.
- PCT/US2006/033079 filed Aug. 24, 2006 International Preliminary Report on Patentability dated Feb. 26, 2008.
- PCT/US2006/033079 filed Aug. 24, 2006 Search Report dated Dec. 19, 2006.
- PCT/US2006/033079 filed Aug. 24, 2006 Written Opinion dated Dec. 19, 2006.
- PCT/US2008/060502 filed Apr. 16, 2008 International Search Report and Written Opinion dated Oct. 16, 2008.
- PCT/US2008/084751 filed Nov. 25, 2008 International Preliminary Report on Patentability dated Jun. 1, 2010.
- PCT/US2008/084751 filed Nov. 25, 2008 Search Report dated May 20, 2009.
- PCT/US2008/084751 filed Nov. 25, 2008 Written Opinion dated May 20, 2009.
- PCT/US2009/033116 filed Feb. 4, 2009 International Preliminary Report on Patentability dated Aug. 10, 2010.
- PCT/US2009/033116 filed Feb. 4, 2009 Search Report dated Mar. 13, 2009.
- PCT/US2009/033116 filed Feb. 4, 2009 Written Opinion dated Mar. 13, 2009.
- PCT/US2009/041051 filed Apr. 17, 2009 Search Report dated Jul. 28, 2009.
- PCT/US2009/041051 filed Apr. 17, 2009 Written Opinion dated Jul. 28, 2009.
- PCT/US2009/054687 filed Aug. 21, 2009 International Preliminary Report on Patentability dated Feb. 22, 2011.
- PCT/US2009/054687 filed Aug. 21, 2009 Search Report dated Oct. 6, 2009.
- PCT/US2009/054687 filed Aug. 21, 2009 Written Opinion dated Oct. 6, 2009.
- "Ascension to Launch New 3D Guidance™ Tracker at TCT 2006." Press Releases from Ascension website: www.ascension-tech.com/news/press_101106.php, last accessed Dec. 1, 2006.
- Acuson—The Value of Vision, AcuNav Diagnostic Ultrasound Catheter, 2000.
- Advertising flyer for GAVECEL™—The Italian Group for Long Term Venous Access Devices, for program on International Meeting on PICC's, Midline Catheters and Long Term Venous Access Devices in Catholic University, Rome, Italy on Dec. 3, 4, 5, 2008.
- Alexander, GD et al, The Role of Nitrous Oxide in Postoperative Nausea and Vomiting, Collection of Abstracts Presented at the International Anesthesia Research Society by various speakers, 58th Congress, Mar. 12-14, 1984, *Anesthesia and Analgesia*, pp. 175-284, vol. 63, 1984.
- Allan, P.L. et al, Role of Ultrasound in the Assessment of Chronic Venous Insufficiency, *Ultrasound Quarterly*, vol. 17, No. 1, pp. 3-10, 2001.
- Andropoulos, et al. "A Controlled Study of the Transesophageal Echocardiography to Guide Central Venous Catheter Placement in Congenital Heart Surgery Patients." *The International Anesthesia Research Society*, vol. 89, pp. 65-70, 1999.
- Anonymous author, Correct Catheter Placement with a low-impact, reliable and economical method, <<http://www.cvc-partner.com/index.cfm?103A955CC6844BF58ACFE3C9C1471959>>, last accessed Dec. 22, 2011.
- Arai, J et al, Detection of Peripherally Inserted Central Catheter Occlusion by in-line Pressure Monitoring, *Paediatr Anaesth*, pp. 621-624, vol. 12 No. 7, Sep. 2002.
- Arrow International, Inc., The Arrow-Johans RAECG Adapter-Making Proper Central Venous Catheter Placement More Reliable (Module No. EG-04900), Technical Report 1987, USA.
- Aslamy, et al. "MRI of Central Venous Anatomy: Implications for Central Venous Catheter Insertion." *American College of Chest Physicians*, Jun. 8, 2009.
- AU 2006283022 filed Aug. 24, 2006 Office Action dated Dec. 22, 2010.
- AU 2008329807 exam requested Aug. 13, 2012 Examination Report No. 1 dated Feb. 15, 2013.
- AU 2011289513 filed Jan. 21, 2013 Examiner's Report dated Jul. 5, 2013.
- AU 2012202293 filed Apr. 19, 2012 Examination Report No. 1 dated Apr. 24, 2013.
- AU 2013204243 filed Apr. 12, 2013 Examiner's Report dated Jun. 5, 2013.
- Aurora® System Technical Specifications, Oct. 2003.
- B. Braun Website, "The Optimal Position of the Central Venous Catheter." <http://www.cvcpartner.com/index.cfm?18F1BDEA1310466194960A39F4E90968> (2009).
- B. Braun, Certofix Central Venous Catheter for Placement Using the Seldinger Technique with Simultaneous ECG Lead Option, Feb. 2010.
- Bailey, SH et al, Is Immediate Chest Radiograph Necessary after Central Venous Catheter Placement in a Surgical Intensive Care Unit?, *Am J Surg*, pp. 517-522, vol. 180 No. 6, Dec. 2000.
- Bankier, Alexander A., Azygos Arch Cannulation by Central Venous Catheters: Radiographic Detection of Malposition and Subsequent Complications, *Journal of Thoracic Imaging* 12:64-69 (1997).
- Barber, JM et al, A Nurse led Peripherally Inserted Central Catheter Line Insertion Service is Effective with Radiological Support, *Clin Radiol*, pp. 352-354, vol. 57 No. 5, May 2002.
- Bard Access Systems, Sherlock Tip Location System, 5 pages, 2006.
- Bard Access Systems, Site Rite Vascular Access Ultrasound System, 4 pages, 2005.
- Benchimol, Alberto et al, Right Atrium and Superior Vena Cava Flow Velocity in Man Measured with the Doppler-Catheter Flowmeter-Telemetry System, *The Amer Journal of Medicine*, pp. 303-309, vol. 48, Mar. 1970.
- BioAdvance Lumen Vu, Greenhouse Fund Feb. 2004 Recipient, www.bioadvance.com <<http://www.bioadvance.com>>, 2005.
- Borgobello, Bridget, App allows users to view electrocardiograms on smartphones dated Oct. 15, 2010; printed from <http://www.gizmag.com/app-to-view-electrocardiograms-on-smartphones/16664/> on Feb. 4, 2011.
- Buehrle, Douglas, PICC Placement in Humans using Electromagnetic Detection, <http://www.corpakmedsystems.com/supplement_material/supplementpages/navigator/navarticle.html>, 2008.

(56)

References Cited

OTHER PUBLICATIONS

- C.R. Bard, CathTrack™ Catheter Location System at www.bardaccess.com <<http://www.bardaccess.com>>, last accessed Apr. 28, 2011.
- C.R. Bard, Inc., Bard Electrophysiology Product Catalogue, Bard Catheters, pp. 74-75 (2002), USA.
- CA 2,619,909 filed Aug. 24, 2006 Examiner's Report dated Oct. 26, 2012.
- Cadman, A et al, To Clot or Not to Clot? That is the question in Central Venous Catheters, *Clinical Radiology*, pp. 349-355, vol. 59 No. 4, Apr. 2004.
- Calvert, N. et al, The Effectiveness and Cost-effectiveness of Ultrasound Locating Devices for Central Venous Access: A Systematic Review and Economic Evaluation, *Health Technology Assessment*, vol. 7, No. 12, 2003.
- Cardella, John F. et al., Interventral Radiologic Placement of Peripherally Inserted Central Catheters, *Journal of Vascular and Interventional Radiology* 1993; 4:653-660.
- Carlson, R et al, Secondary Migration of a Central Venous Catheter—A Case Report, *Minerva Anesthesiol*, pp. 927-931, vol. 69 No. 12, Dec. 2003.
- Caruso, L.J et al, A Better Landmark for Positioning a Central Venous Catheter, *J Clinical Monitoring and Computing*, pp. 331-334, vol. 17 No. 6, Aug. 2002.
- Cavatorta, et al., "Central Venous Catheter Placement in Hemodialysis: Evaluation of Electrocardiography Using a Guidewire." *The Journal of Vascular Access*, vol. 2, pp. 45-50, 2001.
- Chalkiadis, GA et al, Depth of Central Venous Catheter Insertion in Adults: An Audit and Assessment of a Technique to Improve Tip Position, *Anaesth Intensive Care*, pp. 61-66, vol. 26 No. 1, Feb. 1998.
- Chamsi-Pasha, Hassan et al, Cardiac Complications of Total Parenteral Nutrition: The Role of Two-Dimensional Echocardiography in Diagnosis, *Annals of the Royal College of Surgeons of England*, pp. 120-123, vol. 71, 1989.
- Chang, Thomas C. et al., Are Routine Ch Ladiographs Necessary After Image-Guided Placement of Internal Jugular Central Venous Access Devices?, *AJR* Feb. 1998;170:335-337.
- Chaturvedi et al., "Catheter Malplacement During Central Venous Cannulation Through Arm Veins in Pediatric Patients." *Journal of Neurosurgical Anesthesiology*, vol. 15, No. 3 pp. 170-175, Jan. 2003.
- Chen, Zhongping et al, Optical Doppler Tomography: Imaging in vivo Blood Flow Dynamics Following Pharmacological Intervention and Photodynamic Therapy, 7 pages, vol. 67, *Photochemistry and Photobiology*, 1998.
- Cheng, KI et al, A Novel Approach of Intravenous Electrocardiograph Technique in Correct Position the Long-Term Central Venous Catheter, *Kaohsiung J Med Sci*, pp. 241-247, vol. 16 No. 5, May 2000 (Abstract only).
- Cheung, P., et al., The Effect of a Disposable Probe Cover on Pulse Oximetry, *Anaesth Intensive Care* 2002; 30: 211-214.
- Chu, et al., "Accurate Central Venous Port-A Catheter Placement: Intravenous Electrocardiography and Surface Landmark Techniques Compared by Using Transesophageal Echocardiography." *The International Anesthesia Research Society*, vol. 98, pp. 910-914, 2004.
- Claasz, Antonia et al, A Study of the Relationship of the Superior Vena Cava to the Bony Landmarks of the Sternum in the Supine Adult: Implications for Magnetic Guidance Systems, *Journal*, vol. 12 No. 3, *JAVA*, Jul. 24, 2007.
- Clifford, et al. "Assessment of Hepatic Motion Secondary to Respiration for Computer Assisted Interventions." *Computer Aided Surgery*, vol. 7, pp. 291-299, 2002.
- CN 200880012117.4 filed Apr. 16, 2008 First Office Action dated Dec. 23, 2011.
- CN 200880012117.4 filed Apr. 16, 2008 Second Office Action dated Oct. 8, 2012.
- CN 200880012117.4 filed Apr. 16, 2008 Third Office Action dated Apr. 27, 2013.
- CN 200880125528.4 filed Nov. 25, 2008 First Office Action dated Jun. 5, 2012.
- U.S. Appl. No. 13/118,138, filed May 27, 2011 Final Office Action dated Apr. 3, 2013.
- U.S. Appl. No. 13/118,138, filed May 27, 2011 Non-Final Office Action dated Oct. 3, 2012.
- U.S. Appl. No. 13/206,396, filed Aug. 9, 2011 Non-Final Office Action dated Feb. 27, 2014.
- U.S. Appl. No. 13/213,622, filed Aug. 19, 2011 Final Office Action dated Feb. 19, 2013.
- U.S. Appl. No. 13/213,622, filed Aug. 19, 2011 Non-Final Office Action dated Jul. 31, 2012.
- U.S. Appl. No. 13/283,395, filed Oct. 27, 2011 Non-Final Office Action dated Apr. 23, 2013.
- U.S. Appl. No. 13/336,919, filed Dec. 23, 2011 Advisory Action dated May 23, 2013.
- U.S. Appl. No. 13/336,919, filed Dec. 23, 2011 Final Office Action dated Mar. 1, 2013.
- U.S. Appl. No. 13/336,919, filed Dec. 23, 2011 Non-Final Office Action dated Oct. 16, 2012.
- U.S. Appl. No. 13/337,987, filed Dec. 27, 2011 Non-Final Office Action dated Mar. 15, 2013.
- U.S. Appl. No. 29/428,649, filed Aug. 1, 2012 Notice of Allowance dated Jul. 5, 2013.
- Valdivieso, J.R. Perez, et al., Evaluation of a formula for optimal positioning of a central venous catheter inserted through the right internal jugular vein, *Rev. Esp. Anesthesiol. Reanim.* 2003; 50: 77-79.
- VasoNova Inc, Vascular navigation system for accurate placement of PICCs, *Start-Up Emerging Medical Ventures*, pp. 44-45, vol. 14 No. 7, Jul.-Aug. 2009.
- Vesely, Thomas M. et al., Central Venous Catheter Tip Position: A Continuing Controversy, *J Vasc Intery Radiol* 2003; 14:527-534.
- VIASYS Health Care Inc. Cortrak® Fact Sheet, 2005.
- VIASYS Healthcare MedSystems, Navigator® Benefits, 2008.
- VIASYS Healthcare MedSystems, Navigator® Research in Cost Justification, 2008.
- VIASYS MedSystems, Cortrak™ Systems Brochure, 2005.
- Volcano ComboMap Features and Benefits/Technical Specifications, 2 pages, 2011.
- Watters, et al. "Use of Electrocardiogram to Position Right Atrial Catheters During Surgery." *Annals of Surgery*, vol. 225, No. 2, pp. 165-171, 1997.
- Welch Allyn Cardioperfect® PC-Based Resting ECG, 2003.
- Wilson, R. G. et al, Right Atrial Electrocardiography in Placement of Central Venous Catheters, *The Lancet*, pp. 462-463, Feb. 27, 1988.
- Wong, Jeffrey J. et al., Azygos Tip Placement for Hemodialysis Catheters in Patients with Superior Vena Cava Occlusion, *Cardiovasc Intervent Radiol* (2006) 29:143-146.
- Worley, Seth J. "Use of a Real-Time Three-Dimensional Magenetic Navigation System for Radiofrequency Ablation of Accessory Pathways." *PACE*, vol. 21 pp. 1636-1643, Aug. 1998.
- Yilmazlar A et al, Complications of 1303 Central Venous Cannulations, *J R Soc Med*, pp. 319-321, vol. 90 No. 6, Jun. 1997 (Abstract only).
- Yoon, SZ et al, Usefulness of the Carina as a Radiographic Landmark for Central Venous Catheter Placement in Paediatric Patients, *Br J Anaesth*, Jul. 2005.
- Yoshida, Teruhisa et al, Detection of Concealed Left Sided Accessory Atrioventricular Pathway by P Wave Signal Averaged Electrocardiogram, *J Am Coll Cardiol*, pp. 55-62, 1999.
- Zaaroor, et al. "Novel Magnetic Technology for Intraoperative Intracranial Frameless Navigation: In Vivo and in Vitro Results." *Neurosurgery*, vol. 48, No. 5, pp. 1100-1107, May 2001.
- Zachariou, Zacharias et al., Intra-atrial ECG recording: a new and safe method for implantation of Broviac catheters in children, *Pediatr Surg Int* (1994) 9: 457-458.
- CN 200880125528.4 filed Nov. 25, 2008 Second Office Action dated Mar. 6, 2013.
- CN 200880125528.4 filed Nov. 25, 2008 Third Office Action dated Jul. 1, 2013.
- CN 200980123021.X filed Dec. 17, 2010 First Office Action dated Nov. 19, 2012.
- CN 200980144663.8 filed May 9, 2011 First Office Action dated Dec. 5, 2012.

(56)

References Cited

OTHER PUBLICATIONS

- Colley, Peter S et al, ECG-Guided Placement of Sorenson CVP Catheters via Arm Veins, *Anesthesia and Analgesia*, pp. 953-956, vol. 63, 1984.
- Collier, PE et al, Cardiac Tamponade from Central Venous Catheters, *Am J Surg*, pp. 212-214, vol. 176 No. 2, Aug. 1998.
- ComboWire® Pressure/Flow Guide Wire Ref 9500 Series, Instructions for Use, Apr. 2011.
- Corsten, et al., "Central Placement Catheter Placement Using the ECG-Guided Cavafix-Certodyn SD Catheter." *Journal of Clinical Anesthesiology*, vol. 6, Nov./Dec. 1994.
- Cucchiara, Roy et al, Time Required and Success Rate of Percutaneous Right Atrial Catheterization: Description of a Technique, *Canad. Anaesth. Soc. J.*, pp. 572-573, vol. 27, No. 6, Nov. 1980.
- Cullinane, DC et al, The Futility of Chest Roentgenograms Following Routine Central Venous Line Changes, *Am J Surg*, pp. 283-285, vol. 176 No. 3, Sep. 1998.
- Curet, Myriam J. et al., University and Practice-based Physicians' Input on the Content of a Surgical Curriculum, *The American Journal of Surgery®* vol. 178 Jul. 1999, 78-84.
- David, et al., "Is ECG-Guidance a Helpful Method to Correctly Position a Central Venous Catheter During Prehospital Emergency Care?" *ACTA Anaesthesiologica Scandinavica*, vol. 49, pp. 1010-1014, 2005.
- DELTEC Cath-Finder® Tracking System Operation Manual, 1994.
- Egelhof, Petra, Effects of Somatostatin on Portal Blood Flow and Portal Vein Pressure in Patients with Portal Hypertension due to Liver Cirrhosis Invasive Monitoring during TIPSS Procedures, Dissertation submitted to: Technical University of Munich, Faculty of Medicine, May 13, 2002; Date of examination: Feb. 26, 2003.
- Engelhardt, W et al, ECG-Controlled Placement of Central Venous Catheters in Patients with Atrial Fibrillation, *Anaesthesist*, pp. 476-479, vol. 38 No. 9, Sep. 1989 (Abstract only).
- EP 08855396.1 filed Jun. 15, 2010 European Search Report dated Jul. 31, 2012.
- EP 08855396.1 filed Jun. 15, 2010 Intent to Grant dated Jul. 5, 2013.
- EP 09707467.8 supplemental European search report dated Jun. 18, 2013.
- EP 09808901.4 filed Aug. 21, 2009 European Search Report dated May 23, 2012.
- EP 09808901.4 filed Aug. 21, 2009 Examination Report dated May 10, 2013.
- EP 09813632.8 filed Apr. 5, 2011 European Search Report dated Jul. 4, 2012.
- EP 09813632.8 filed Apr. 5, 2011 Office Action dated Apr. 30, 2013.
- EP 12177438.4 filed Jul. 23, 2012 European Search Report dated Dec. 4, 2012.
- EP 12177438.4 filed Jul. 23, 2012 extended European Search Report dated Mar. 25, 2013.
- Fearon, William F et al, Evaluating Intermediate Coronary Lesions in the Cardiac Catheterization Laboratory, vol. 4, No. 1, 7 pages, *Reviews in Cardiovascular Medicine*, 2003.
- Felleiter P et al, Use of Electrocardiographic Placement Control of Central Venous Catheters in Austria, *Acta Med Austriaca*, pp. 109-113, vol. 26 No. 3, 1999 (Abstract only).
- Forauer, AR et al, Change in Peripherally Inserted Central Catheter Tip Location with Abduction and Adduction of the Upper Extremity, *J Vasc Interv Radiol*, pp. 1315-1318, vol. 11 No. 10, Nov.-Dec. 2000.
- Frassinelli, P et al, Utility of Chest Radiographs after Guidewire Exchanges of Central Venous Catheters, *Crit Care Med*, pp. 611-615, vol. 26 No. 3, Mar. 1998.
- Frazin L et al, A Doppler Guided Retrograde Catheterization System, *Cathet. Cardiovasc Diagn*, pp. 41-50, May 1992.
- French, PJ et al, Sensors for Catheter Applications, *Sensors Update*, vol. 13 Issue 1 pp. 107-153, Dec. 2003.
- GB Application 0800474.9 filed Aug. 24, 2006 Office Action dated Aug. 9, 2010.
- GB Application 0800474.9 filed Aug. 24, 2006 Office Action dated Mar. 17, 2010.
- Gebauer, B et al, Ultrasound and Fluoroscopy-guided Implantation of Peripherally Inserted Central Venous Catheters (PICCs), *ROFO*, pp. 386-391, vol. 176 No. 3, Mar. 2004 (Abstract only).
- Gebhard, et al., "The accuracy of Electrocardiogram-Controlled Central Line Placement." *The International Anesthesia Research Society*, vol. 104, No. 1 Jan. 2007.
- Gjendemsjo, Anders, et al., Energy and Power, *The Connexions Project*, Version 1.2, Feb. 20, 2004.
- Gladwin, MT et al, Cannulation of the Internal Jugular Vein: is postprocedural chest radiography always necessary?, *Crit Care Med*, 33 pages, Oct. 2000.
- Gonzales, et al. "Peripherally Inserted Central Catheter Placement in Swine Using Magnet Detection." *Journal of Intravenous Nursing*, vol. 22, No. 3, May/Jun. 1999.
- Greenall, M.J. et al, Cardiac Tamponade and Central Venous Catheters, *British Medical Journal*, pp. 595-597, Jun. 14, 1975.
- Guillory, "Basic Principles of Technologies for Catheter Localization." C.R. Bard internal paper, Oct. 20, 2004.
- Guth, AA, Routine Chest X-rays after Insertion of Implantable Long-Term Venous Catheters: Necessary or Not?, *Am Surg*, pp. 26-29, vol. 67 No. 1, Jan. 2001 (Abstract only).
- Hill, Bradley et al, Abstract of article discussing VasaNova VPS as guide for placement of PICCs. 2009.
- Hill, Bradley, Identifying the Caval-Atrial Junction Using Smart-Catheter Technology presentation, 22nd Annual Scientific Meeting of the AVA in Savannah, Georgia, Sep. 13, 2008.
- Hoffman, Thomas et al, Simultaneous Measurement of Pulmonary Venous Flow by Intravascular Catheter Doppler Velocimetry and Transesophageal Doppler Echocardiography: Relation to Left Atrial Pressure and Left Atrial and Left Ventricular Function, pp. 239-249, *J Am Coll Cardiol*, Jul. 1995.
- Hoffmann, et al. "New Procedure in Transesophageal Echocardiography: Multiplane Transesophageal Echocardiography and Transesophageal Stress Echocardiography." *Herz*, vol. 18, No. 5, pp. 269-277, Oct. 1993.
- Iacopino, Domenico Gerardo et al, Intraoperative Microvascular Doppler Monitoring of Blood Flow within a Spinal Dural Arteriovenous Fistula: A Precious Surgical Tool, vol. 10, 5 pages, *Neurosurg. Focus*, Feb. 2001.
- Joosting, Jean-Pierre, "Dual-interface RFID-compatible EEPROM enables remote access to electronic device parameters," *EE Times*, Mar. 8, 2010.
- JP 2008-528151 filed Aug. 24, 2006 Notice of Grant dated May 6, 2012.
- JP 2010-504220 filed Sep. 3, 2009 Final Office Action dated Apr. 18, 2013.
- JP 2010-504220 filed Sep. 3, 2009 Office Action dated May 21, 2012.
- Kim, Ko et al, Positioning Internal Jugular Venous Catheters using the Right Third Intercostal Space in Children, *Acta Anaesthesiol Scand*, pp. 1284-1286, vol. 47 No. 10, Nov. 2003.
- Schummer, W et al, ECG-guided Central Venous Catheter Positioning: Does it detect the Pericardial Reflection rather than the Right Atrium?, *Eur J Anaesthesiol*, pp. 600-605, vol. 21 No. 8, Aug. 2004 (Abstract only).
- Schummer, W et al, Intra-Atrial ECG is not a Reliable Method for Positioning Left Internal Jugular Vein Catheters, *Br J Anaesth*, pp. 481-486, vol. 91 No. 4, Oct. 2003.
- Schummer, W, Central Venous Catheter—The Inability of "Intra-Atrial ECG" to prove Adequate Positioning, *Br J Anaesth*, pp. 193-198, vol. 93 No. 2, Aug. 2004.
- Schuster, M. et al., The carina as a landmark in central venous catheter placement, *British Journal of Anaesthesia* 85 (2): 192-4 (2000).
- Siela, Debra, Using Chest Radiography in the Intensive Care Unit, *Crit Care Nurse* Aug. 1, 2002 vol. 22 No. 4, pp. 18-27.
- Silindir, M. et al., "Sterilization Methods and the Comparison of E-Beam Sterilization with Gamma Radiation Sterilization," *FABAD J. Pharm. Sci.*, 34, 43-53, 2009.
- Simon, et al., "Central Venous Catheter Placement in Children: Evaluation of Electrocardiography Using J-Wire." *Paediatric Anaesthesia* vol. 9, pp. 501-504, 1999.

(56)

References Cited

OTHER PUBLICATIONS

Smith, Brigham, et al., Intravenous electrocardiographic guidance for placement of peripherally inserted central catheters, *Journal of Electrocardiology* 43 (2010) 274-278.

Stark, DD et al, Radiographic Assessment of Venous Catheter Position in Children: Value of the Lateral View, *Pediatric Radiology*, pp. 76-80, vol. 14 No. 2, 1984.

Starkhammar et al. "Cath-Finder Catheter Tracking System: A New Device for Positioning of Central Venous Catheters. Early Experience from Implantation of Brachial portal Systems." *Acta Anaesthesiol Scandinavica*, vol. 34, No. 4 pp. 296-300, May 1990.

Starkhammer, H et al, Central Venous Catheter Placement using Electromagnetic Position Sensing: A Clinical Evaluation, *Biomed. Instrum Technol*, vol. 30 No. 2, pp. 164-170; Mar.-Apr. 1996.

Starr, David S et al, EKG Guided Placement of Subclavian CVP Catheters Using J-Wire, pp. 673-676, *Ann. Surg.*, Dec. 1986.

Stas, M et al, Peroperative Intravascular Electrographic Control of Catheter Tip Position in Access Ports Placed by Venous Cut-Down Technique, *EJSO*, pp. 316-320, vol. 27, 2001.

Stereotaxis Magetic Navigation System with Navigant™ User Interface, 2005 Brochure.

Stereotaxis, Expanding the Possibilities of Interventional Medicine: Remote Navigation and Automation, pp. 1-8, Apr. 2011.

Tepa® Health Innovation PC based ECG System Introduction and Technical Specifications, EKG Master USB, 2 pages, Nov. 2003.

The FloWire Doppler Guide Wire located <<http://www.volcanocorp.com/products/flowire-doppler-guide-wire.php>>, 2011.

Traxal Technologies, Tracking Technology website overview: www.traxal.com/rd/rd_classroom_trackingtechnology.htm, last accessed Dec. 1, 2006.

UAB Health Systems, Arrhythmias, retrieved from <http://www.health.uab.edu/14564/> on Nov. 15, 2007, 12 pages.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Advisory Action dated Jun. 22, 2009.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Appeal Board Decision dated Sep. 17, 2012.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Final Office Action dated Apr. 8, 2010.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Final Office Action dated Jan. 30, 2009.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Non-Final Office Action dated Mar. 28, 2013.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Non-Final Office Action dated Sep. 25, 2009.

U.S. Appl. No. 11/466,602, filed Aug. 23, 2006 Notice of Allowance dated Dec. 3, 2012.

U.S. Appl. No. 11/552,094, filed Oct. 23, 2006 Notice of Allowability dated Apr. 2, 2010.

U.S. Appl. No. 11/552,094, filed Oct. 23, 2006 Non-Final Office Action dated Apr. 27, 2009.

U.S. Appl. No. 11/552,094, filed Oct. 23, 2006 Notice of Allowance dated May 20, 2010.

U.S. Appl. No. 12/104,253, filed Apr. 16, 2008 Final Office Action dated Jul. 27, 2011.

U.S. Appl. No. 12/104,253, filed Apr. 16, 2008 Non-Final Office Action dated Nov. 29, 2010.

U.S. Appl. No. 12/323,273, filed Nov. 25, 2008 Non-Final Office Action dated Jun. 8, 2012.

U.S. Appl. No. 12/369,625, filed Feb. 11, 2009 Final Office Action dated Feb. 23, 2012.

U.S. Appl. No. 12/369,625, filed Feb. 11, 2009 Notice of Allowance dated Oct. 5, 2012.

U.S. Appl. No. 12/369,625, filed Feb. 11, 2009 Notice of Panel Decision dated Aug. 1, 2012.

U.S. Appl. No. 12/369,625, filed Feb. 11, 2009 Non-Final Office Action dated Jul. 20, 2011.

U.S. Appl. No. 12/426,175, filed Apr. 17, 2009 Non-Final Office Action dated Dec. 3, 2012.

U.S. Appl. No. 12/427,244, filed Apr. 21, 2009 Non-Final Office Action dated Jan. 19, 2012.

U.S. Appl. No. 12/545,762, filed Aug. 21, 2009 Final Office Action dated Mar. 7, 2013.

U.S. Appl. No. 12/545,762, filed Aug. 21, 2009 Non-Final Office Action dated Aug. 1, 2012.

U.S. Appl. No. 12/557,401, filed Sep. 10, 2009 Non-Final Office Action dated Apr. 24, 2012.

U.S. Appl. No. 12/575,456, filed Oct. 7, 2009 Non-Final Office Action dated Oct. 5, 2012.

U.S. Appl. No. 12/715,556, filed Mar. 2, 2010 Non-Final Office Action dated Sep. 13, 2012.

U.S. Appl. No. 12/854,083, filed Aug. 10, 2010 Non-Final Office Action dated Jan. 29, 2013.

U.S. Appl. No. 12/878,915, filed Sep. 9, 2010 Final Office Action dated Sep. 26, 2012.

U.S. Appl. No. 12/878,915, filed Sep. 9, 2010 Non-Final Office Action dated Mar. 15, 2012.

U.S. Appl. No. 12/878,915, filed Sep. 9, 2010 Notice of Allowance dated Jan. 8, 2013.

U.S. Appl. No. 12/900,750, filed Oct. 8, 2010 Final Office Action dated Dec. 3, 2013.


U.S. Appl. No. 12/900,750, filed Oct. 8, 2010 Non-Final Office Action dated Apr. 10, 2014.

U.S. Appl. No. 12/900,750, filed Oct. 8, 2010 Non-Final Office Action dated Jun. 3, 2013.

JP 2013-524183 filed Feb. 8, 2015 First Office Action dated Jun. 24, 2015.

U.S. Appl. No. 13/206,396, filed Aug. 9, 2011, Final Office Action dated Jun. 10, 2015.

* cited by examiner

**FIG. 1**




FIG. 2A




FIG. 2B





FIG. 2C

**FIG. 3**









FIG. 4A

FIG. 4B

**FIG. 4C**






FIG. 6A





FIG. 6B

**FIG. 7**




FIG. 8

RUGGEDIZED ULTRASOUND HYDROGEL INSERT

CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 61/563,382, filed Nov. 23, 2011, and titled “Ruggedized Ultrasound Hydrogel Insert,” and U.S. Provisional Application No. 61/556,626, filed Nov. 7, 2011, and titled, “Systems and Methods for Ultrasound-Based Pneumothorax,” each of which is incorporated herein by reference in its entirety.

BRIEF SUMMARY

Briefly summarized, embodiments of the present invention are directed to a ruggedized hydrogel product that is formulated to withstand the effects of high-energy sterilization procedures, such as gamma beam and electron beam sterilization, without significant structural degradation. This enables the hydrogel product to be suitable for use in medical applications where sterile components are required.

In one embodiment a ruggedized hydrogel product is disclosed and comprises a gel component, water for hydrating the gel component, and at least one free radical absorber component that is capable of absorbing free radicals produced when the hydrogel product is sterilized via high-energy sterilization procedures. The free radical absorber component in one embodiment includes potassium metabisulfite and ascorbic acid.

The ruggedized hydrogel product can be included with an ultrasound probe to provide an acoustically transparent interface between the probe and the skin of a patient. In one embodiment, the hydrogel is configured as an insert included with a cap that can be removably attached to the probe. In another embodiment, the hydrogel is configured as a slab that is attached to the bottom of a pancake probe. In addition, other configurations can also be employed.

These and other features of embodiments of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of embodiments of the invention as set forth hereinafter.

BRIEF DESCRIPTION OF THE DRAWINGS

A more particular description of the present disclosure will be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. Example embodiments of the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:

FIG. 1 is a perspective view of a cap for an ultrasound probe including a ruggedized hydrogel insert according to one embodiment;

FIGS. 2A-2C are various views of a tray for housing the cap of FIG. 1 according to one embodiment;

FIG. 3 shows the cap of FIG. 1 disposed in the tray of FIGS. 2A-2C according to one embodiment;

FIGS. 4A and 4B are exploded front and side perspective views of an ultrasound probe including the cap of FIG. 1 according to one embodiment;

FIG. 4C is an assembled front perspective view of the ultrasound probe and cap of FIGS. 4A and 4B according to one embodiment;

FIG. 5 shows an ultrasound system including a probe for use with a patient according to one embodiment;

FIGS. 6A and 6B are various views of an ultrasound probe including a ruggedized hydrogel product according to one embodiment;

FIG. 7 is a top view of an ultrasound probe including a ruggedized hydrogel product according to one embodiment; and

FIG. 8 is a flow diagram showing preparation and dispensing of a ruggedized hydrogel product according to one embodiment.

DETAILED DESCRIPTION OF SELECTED EMBODIMENTS

Reference will now be made to figures wherein like structures will be provided with like reference designations. It is understood that the drawings are diagrammatic and schematic representations of exemplary embodiments of the present invention, and are neither limiting nor necessarily drawn to scale.

For clarity it is to be understood that the word “proximal” refers to a direction relatively closer to a clinician using the device to be described herein, while the word “distal” refers to a direction relatively further from the clinician. For example, the end of a catheter placed within the body of a patient is considered a distal end of the catheter, while the catheter end remaining outside the body is a proximal end of the catheter. Also, the words “including,” “has,” and “having,” as used herein, including the claims, shall have the same meaning as the word “comprising.”

Embodiments of the present invention are generally directed to a ruggedized hydrogel product that is formulated to withstand the effects of high-energy sterilization procedures, such as gamma beam and electron beam (“e-beam”) sterilization, without significant structural degradation. This enables the hydrogel product to be suitable for use in medical applications where sterile components are required.

For example, the ruggedized hydrogel product can be included in one embodiment for use with an ultrasound probe. Particularly, the hydrogel product in one embodiment is positioned between a head portion of the probe and the patient’s skin so as to act as an acoustically coupling interface during use of the probe in imaging subcutaneous tissue of the patient. This enables ultrasound signals emitted and received by the probe head to be efficiently transmitted between the head and the patient’s body through the hydrogel, thus improving the quality of images produced by the ultrasound signals.

In addition, the hydrogel includes a substantial amount of water, which is exuded therefrom during use, thus providing a low friction interface that enables smooth sliding movement of the probe atop the skin. The relatively high water content of the hydrogel also mimics the composition of tissue in the patient’s body, thus providing a relatively uniform medium for the transmission of ultrasound signals into and out of the body. Moreover, the hydrogel as disclosed herein is solid but compliant so as to conform to variations in the skin surface, thus enhancing the ability to maintain acoustic coupling between the probe head and the patient’s body when the probe is slid over the patient’s skin.

As mentioned above, the hydrogel product is both biocompatible and sterilizable so as to be usable in standard clinical environments. In particular, the hydrogel formulations disclosed herein can be subjected to standard sterilizing procedures, such as gamma beam and electron beam sterilization, without liquefying or otherwise physically degrading. This enables the hydrogel to successfully and safely undergo sterilization procedures together with other components to be sterilized, such as within a kit for instance, which increases manufacturing efficiency. In addition, the hydrogel can be configured to withstand other forms of sterilization/sterilizing materials, including ultraviolet light, hydrogen peroxide, ozone, and corona discharge treatment, in one embodiment. As used herein, "hydrogel" is understood to include a polymer network dispersed in water, often exhibited as a semi-solid gel.

Reference is made to FIG. 1, which depicts a cap 10 for use with an ultrasound probe, such as the probe 30 shown in FIGS. 4A-4C, according to one embodiment. The cap 10 is configured to operably attach to the probe 30 in a snap-fit or other suitable arrangement so as to cover at least a portion of a head portion 32 of the probe. Further details regarding the ultrasound probe 30 are given further below.

A hydrogel insert 12 including a hydrogel product configured in accordance with one embodiment is included with the cap 10. As shown in FIG. 1, the insert 12 is disposed in an opening 14 defined in the cap 10 so as to be secured in the configuration shown. The distal end of the insert 12 defines a concave shape to act, in one embodiment, as a standoff component for providing a physical separation between the ultrasound probe 30 (FIGS. 4A-4C) and the patient's skin, thus preventing compression of superficial veins beneath the skin and therefore enabling suitable imaging thereof. In the present embodiment, a fixture 16 is included on the cap 10 for receipt of a needle guide to help guide a needle into the patient after a suitable vessel has been found via ultrasound imaging. Further details regarding the cap and needle guide can be found in U.S. Publication No. 2011/0313293, filed Aug. 9, 2011, and U.S. Publication No. 2012/0165679, filed Dec. 22, 2011, and titled "Selectable Angle Needle Guide", each of which is incorporated herein by reference in its entirety. It should be noted that the discussion herein concerning the hydrogel component and its use with an ultrasound probe is merely an example of one implementation thereof and should not be considered limiting of the range of possible uses for the hydrogel product.

FIGS. 2A-2C show a tray 20 that serves as a mold in the present embodiment for forming the hydrogel insert 12 of FIG. 1, as will be described. The tray 20 includes a suitable material such as a thermoplastic and defines a cavity 22 for receiving various components therein. Specifically, a cap cavity portion 24 is defined in the cavity 22 and is shaped to removably receive therein the cap 10 of FIG. 1. A convexly-shaped hydrogel insert cavity portion 26 is defined within the cap cavity portion 24 and is shaped to provide a mold surface and volume for defining the hydrogel insert 12 when the insert is manufactured, as will be described further below. Also included is a cavity area 28 adjacent the cap cavity portion 24 to provide a space where a needle guide can be disposed if attached to the cap.

FIG. 3 shows the cavity 22 of the tray 20 with the cap 10 disposed in the cap cavity portion 22 thereof. With the cap 10 so positioned a volume is defined, as mentioned, proximate the distal end of the cap 10 and the hydrogel insert cavity portion 26 in which the hydrogel product can be disposed and

cured, as discussed further below, in order to form the hydrogel insert 12 in an attached configuration with the cap, as seen in FIG. 1.

FIGS. 4A-4C show the manner of attachment of the cap 10 to the head portion 32 of the ultrasound probe 30. Surface features on the cap 10 and the head 32 are included to enable the cap to be removably attached to the head in a friction fit arrangement, though other attachment schemes may also be used. This places the hydrogel component of the insert 12 at the distal end of the probe 30 to provide an ultrasonically transparent interface between transducer elements disposed in the probe head 32 and the patient's skin. Again, the probe, the cap, and the manner in which the hydrogel component is configured and used can vary from what is shown and described herein.

As mentioned, the hydrogel product of the insert 12 of the cap 10 is used in medical applications to assist with ultrasonic imaging procedures, such as imaging a subcutaneous vessel in preparation for insertion of a catheter, needle, or other medical device therein. As such, the cap 10 and accompanying hydrogel insert must often be sterilized prior to use so as to prevent transmission of microbes, diseases, viruses, bacteria, and so forth. In the present embodiment the hydrogel product is formulated so as to withstand high-energy sterilization procedures that are typically used to sterilize medical devices and equipment.

Specifically, in one embodiment the hydrogel product from which the insert 12 is made includes a ruggedized formulation to provide the desirable qualities discussed above, including the ability to sterilize the hydrogel insert via gamma beam or electron beam sterilization procedures without causing physical degradation of the hydrogel. In one embodiment a hydrogel product is disclosed that includes various components, namely: a gel component to provide the gel structure itself, and water to hydrate the initially dry gel component. In accordance with the present embodiment, one or more free radical absorber components are also included in the composition to absorb free radicals that are produced in the hydrogel as a result of the high-energy sterilization process. Left unchecked, the free radicals cause undesired degradation and liquefying of the hydrogel, rendering it useless for the intended ultrasound-related uses discussed above. By including these absorbers in the hydrogel component, the free radicals are neutralized and are thus unable to cause hydrogel degradation.

According to one embodiment, non-limiting examples of free radical absorbers that can be utilized in the hydrogel of the insert 118 or other implementation include: glutathione, potassium metabisulfite, potassium disulfite, sodium formate, potassium formate, L-ascorbic acid, sodium citrate monobasic, L-glutamic acid monosodium salt, L-glutamic acid, catechin, organic compound-containing thiol, potassium iodide, vitamin E, cysteine, and other suitable absorbers including antioxidants employed in the food and cosmetics industry. Other salt forms of the above compounds can also be employed as suitable free radical absorbers. For instance potassium formate, a salt compound related to sodium formate, can be also be employed as a free radical absorber. In addition to the gel component and free radical absorber components, and water, other additive components can be included, including mixing aids, preservatives, etc.

In light of the above, in one example embodiment a hydrogel product includes the following composition:

TABLE 1

Category	Component	Quantity (percentage by weight, per each hydrogel unit)
Gel Component	Carrageenan Gum & Konjac Gum	About 2.09%
Free Radical Absorber	Potassium Metabisulfite	About 1.86%
Free Radical Absorber	Ascorbic Acid	About 0.025%
Additive	Isopropyl Alcohol	About 0.95%
Hydrating Medium	Deionized Water	About 95.07%

As seen in Table 1, the hydrogel component according to the present embodiment includes a gel component, two free radical absorber components, an additive, and water as a hydrating medium. The gel component in the present embodiment includes a hydrogel powder product, Stabilizer VPB-1, sold under the trademark COYOTE and manufactured by Gum Technology of Tucson, Ariz. Comparable products are attainable from other sources. The Stabilizer VPB-1 powder gel component includes both carrageenan gum and konjac gum and provides the base for the hydrogel product. In one embodiment, the Stabilizer VPB-1 powder gel component includes a particle size of 90% minimum passage through a U.S. Standard 40 mesh sieve and can include potassium chloride and/or calcium chloride to provide standardization thereof.

The free radical absorbers of Table 1 include potassium metabisulfite (also known as potassium disulfite) and ascorbic acid, otherwise known as vitamin C. Each of these provides stability to the hydrogel component in absorbing free radicals created in the hydrogel during subsequent high-energy sterilization procedures. In the present embodiment, the potassium metabisulfite is initially in powder form and possesses a purity of greater than or equal to about 95%. The ascorbic acid is also initially in powder form and possesses a purity equal to or exceeding about 99%. In one embodiment, the above components can generally meet food or nutraceutical grade for use in the present hydrogel product formulation. It is appreciated that the term "powder" herein can include various physical forms including particulate, granular, crystalline, crushed, etc.

The additive isopropyl alcohol ("IPA") in the present embodiment is of USP grade at a purity of equal to or exceeding 99%. The IPA aides in the dissolving and/or mixing of the other ingredients during hydrogel manufacture and also assists in neutralizing the scent of the hydrogel created by the free radical absorbers components. The water serves as the hydrating medium for the hydrogel product and subsequently provides the acoustic transparency necessary for the hydrogel product. In the present embodiment, deionized water is employed to provide an acceptable purity level. However, in other embodiments other forms of water with a low bio-burden or contaminant level can be employed, including sterile water, distilled water, filtered water, etc. Note also that the relative concentrations or inclusion of the various components can be varied from what is shown herein.

FIG. 8 provides a flow diagram 100 describing various stages of the preparation of the hydrogel product described herein. Though directed toward preparation of the hydrogel product having the formulation depicted in Table 1 above, the flow diagram 100 can also be applied to other possible hydrogel formulations, including those additionally described herein. At stage 102 the dry powder gel component, i.e., the Stabilizer VPB-1 powder in the present embodiment, can be subjected to a pre-treatment heating process in order to

reduce or eliminate any bio-burden, or presence of undesired biological entities (microbes, insects, etc.) In the present embodiment, the gel component is subjected to oven heating at about 120 degrees Celsius for about 4 to 5 hours.

At stage 106, a measured amount the pre-treated gel component is combined with measured amounts of the powder forms of the free radical absorber components 104, i.e., the potassium metabisulfite and ascorbic acid in the present embodiment. In one embodiment, combining of these components is achieved via dry-mixing. In another embodiment, the powder components are merely combined without active mixing.

At stage 108, the combined powder from stage 106 is mixed into a vessel with measured amounts of deionized water, represented at block 110, and IPA, represented at block 112. In the present embodiment, the liquid IPA is added to the deionized water already present in the vessel before the dry-mixed powder is introduced into the vessel. In another embodiment, the IPA and water can be added at the same time. A mechanical mixer can be used and the dry-mixed powder added slowly to the deionized water/IPA mixture to ensure dispersion and dissolving of the powder. The hydrated mixture ("hydrogel solution") is mixed for about two minutes after all the components have been added, in the present embodiment.

At stage 114, the hydrogel solution is subjected to a vacuum in order to reduce or eliminate any air bubbles in the mixture. In the present embodiment, the vessel used at stage 108 is a pressure vessel suitable for providing a vacuum so the hydrogel solution need not be transferred to another container. The vacuum is applied to the hydrogel solution a minimum of 10 minutes in the present embodiment so that all or most air bubbles trapped in the solution are released. The hydrogel solution can then be inspected to ensure it is smooth and substantially bubble-free. If not, the vacuum process can be repeated.

At stage 116 the hydrogel solution is heated to a temperature of about 85-90 degrees Celsius to keep it flowable in preparation for dispensing it at stage 118 and completing preparation of the hydrogel product. Of course, the heating temperature and other details of the procedure described herein can be varied in accordance with alterations in the hydrogel formula, intended use, etc., as appreciated by one skilled in the art. In the present embodiment, the hydrogel solution is loaded into a suitable pumping/dispensing device. Note that the dispensing device can also provide the needed heating of the solution shown at stage 116.

With respect to dispensing the hydrogel solution of stage 118, in one embodiment the solution is dispensed into a portion of the tray 20 shown and described in connection with FIGS. 2A-3. In particular, the hydrogel solution can be dispensed into the volume defined by the hydrogel insert cavity portion 26 when the cap 10 is disposed within the tray 20. As mentioned, the portion of the tray 20 that defines the hydrogel insert cavity portion 26 is shaped so as to impart the desired shape of the hydrogel insert 12 (see FIG. 1) when the hydrogel solution solidifies after dispensing.

In the present embodiment, the dispensing stage 118 includes placing the cap 10 (FIG. 1) in the cap cavity portion 24 of the cavity 22 of the tray 20 as shown in FIG. 3. In one embodiment a needle guide can be attached to the cap 10 prior to placing it in the tray 20; if so, the needle guide is disposed in the cavity area 28 of the tray cavity 22 when the cap is placed in the tray.

Once the cap is disposed in the tray, the cap 10 can be treated with a corona discharge treatment process to improve

cap surface characteristics for receipt of the hydrogel solution that will solidify to form the hydrogel insert 12, FIG. 1.

After the corona discharge treatment the hydrogel solution, which is heated as previously described to maintain flowability, is dispensed from a suitable dispenser into the hydrogel insert cavity portion 26 of the tray cavity 22 in sufficient quantity to fill the cavity portion and backfill into the cap 10 via the opening 14 thereof a limited amount. Inspection after filling may indicate if air bubbles are present, the fill was insufficient or non-uniform or messy, etc. such that corrective measures may be taken.

After dispensing of the hydrogel solution into the cap 10 within the tray 20, the tray is left flat for at least 30 seconds in one embodiment to ensure that the hydrogel solution properly cures and solidifies into the hydrogel insert 12 (FIG. 1). As a portion of the hydrogel solution solidifies within the volume defined by the cap 10, attachment between the hydrogel and the cap is achieved. Note that the above-described procedures can be performed for each cap individually or in a batch process where multiple caps are filled with hydrogel solution. Note also that this is but one possible use for the ruggedized hydrogel; other hydrogel applications can also benefit from the principles described herein.

After curing of the hydrogel solution, the cap 10 and newly-formed hydrogel insert 12 can be sterilized by high-energy sterilization procedures without being removed from the tray 20. As described, because of its formulation the hydrogel product can withstand such high-energy sterilization without undesirably degrading and liquefying. In one example, the hydrogel product was exposed to about 30 kGy of ionizing radiation (gamma beam) sterilization without significant resultant hydrogel degradation.

Once sterilization is complete, the tray 20, including the cap 10 and attached hydrogel insert 12 disposed therein, can be packaged, stored, used, etc. For instance, the cap 10 in one embodiment may be attached to and used with an ultrasound probe, such as the probe 30 shown in FIG. 4C.

Below are various examples of preparations of a hydrogel product in accordance with embodiments of the present disclosure.

EXAMPLE 1

A hydrogel product was prepared by first pre-treating about 100 grams of Gum Tech Stabilizer VPB-1 powder in an oven for about four hours at about 120 degrees Celsius. About 86.0 to about 89.9 grams of the pre-treated Stabilizer VPB-1 powder was then combined with about 75.7 to about 80.0 grams of potassium metabisulfite powder and about 1.01 to about 1.06 grams of ascorbic acid powder to form a hydrogel powder. The hydrogel powder was then mixed into an aqueous solution of about 4,000 ml of deionized water and about 40 ml of isopropyl alcohol for approximately two minutes after all of the hydrogel powder had been added to the aqueous solution. A vacuum cycle of about 10 minutes was then applied to the resultant hydrogel solution to remove any air bubbles. The hydrogel solution was then heated to a temperature of from about 85 to about 90 degrees Celsius and dispensed to a tray mold. The molded hydrogel solution was allowed to cure for about 30 seconds to form a completed hydrogel product. Note that the purities and other characteristics of the components of the hydrogel solution of the present example are similar to those described in the above discussion relating to FIG. 8.

EXAMPLE 2

A hydrogel product was prepared by first combining dry powders of the following components in the specified con-

centrations (percentages are w/w- by weight) to form a hydrogel powder: gel component: kappa-carrageenan gum- about 0.7%; iota-carrageenan gum- about 0.3%; konjac gum- about 0.5%; potassium chloride- about 0.010% (about 8 millimolar ("mM")); free radical absorber components: L-ascorbic acid- about 2.5% (about 140 mM); potassium metabisulfite- about 1.33% (about 50 mM); preservatives: propyl 4-hydroxybenzoate- about 0.18% (about 1.0 mM); methyl 4-hydroxybenzoate- about 0.05% (about 0.4 mM). The hydrogel powder was then mixed into an aqueous solution to form a hydrogel solution. The aqueous solution included isopropyl alcohol comprising about 4% (about 500 mM) of the total hydrogel solution and deionized water comprising about 90.66% of the total hydrogel solution. The hydrogel solution was mixed for at least two minutes after all of the hydrogel powder had been added to the aqueous solution. The hydrogel solution was then heated and dispensed to a mold. The molded hydrogel solution was allowed to cure to form a completed hydrogel product.

EXAMPLE 3

A hydrogel product was prepared by first combining dry powders of the following components in the specified concentrations (percentages are w/w- by weight) to form a hydrogel powder: gel component: kappa-carrageenan gum- about 0.7%; iota-carrageenan gum- about 0.3%; konjac gum- about 0.5%; potassium chloride- about 0.010% (about 8 millimolar ("mM")); free radical absorber components: L-ascorbic acid- about 2.5% (about 140 mM); glutathione- about 1.2% (about 40 mM); preservatives: propyl 4-hydroxybenzoate- about 0.18% (about 1.0 mM); methyl 4-hydroxybenzoate- about 0.05% (about 0.4 mM). The hydrogel powder was then mixed into an aqueous solution to form a hydrogel solution. The aqueous solution included isopropyl alcohol comprising about 4% (about 500 mM) of the total hydrogel solution and deionized water comprising about 90.56% of the total hydrogel solution. The hydrogel solution was mixed for at least two minutes after all of the hydrogel powder had been added to the aqueous solution. The hydrogel solution was then heated and dispensed to a mold. The molded hydrogel solution was allowed to cure to form a completed hydrogel product.

EXAMPLE 4

A hydrogel product was prepared by first combining dry powders of the following components in the specified concentrations (percentages are w/w- by weight) to form a hydrogel powder: gel component: kappa-carrageenan gum- about 0.7%; iota-carrageenan gum- about 0.3%; konjac gum- about 0.5%; potassium chloride- about 0.010% (about 8 millimolar ("mM")); free radical absorber components: L-ascorbic acid- about 2.5% (about 140 mM); sodium formate- about 2.0% (about 300 mM); preservatives: propyl 4-hydroxybenzoate- about 0.18% (about 1.0 mM); methyl 4-hydroxybenzoate- about 0.05% (about 0.4 mM). The hydrogel powder was then mixed into an aqueous solution to form a hydrogel solution. The aqueous solution included isopropyl alcohol comprising about 4% (about 500 mM) of the total hydrogel solution and deionized water comprising about 89.76% of the total hydrogel solution. The hydrogel solution was mixed for at least two minutes after all of the hydrogel powder had been added to the aqueous solution. The hydrogel solution was then heated and dispensed to a mold. The molded hydrogel solution was allowed to cure to form a completed hydrogel product.

It is appreciated that in other embodiments the formulations identified in Examples 2-4, can omit the preservatives

propyl 4-hydroxybenzoate and methyl 4-hydroxybenzoate from the hydrogel product formulation. In another embodiment, the free radical absorber ascorbic acid can be omitted from the hydrogel product formulation. In yet another embodiment, a suitable antibacterial/antimicrobial component could be added to the hydrogel formulation. IPA can be varied in concentration, such as from about one to about five percent by weight in one embodiment, or omitted from the composition in one embodiment. Indeed, if IPA is omitted from the hydrogel formulation, a small amount could still be added to an external portion of the hydrogel product post-manufacture so as to assist in masking any unpleasant smell of the hydrogel. Other aromatic or fragrant substances can optionally be used to mask the hydrogel odor. It is also appreciated that other gel components in addition to those listed herein can be employed, including polysaccharide-based gel components, for instance.

In yet another embodiment, it is appreciated that the hydrogel product can include a component to render the hydrogel bacteriostatic. In such a case, it may be chosen to not sterilize the hydrogel product, but rather rely on its bacteriostatic qualities. In one embodiment, a suitable substance, such as chlorhexadine, can be added to the hydrogel component to render it bacteriostatic. In this instance, the IPA could be included or omitted from the hydrogel formulation.

Reference is now made to FIG. 5 in describing one possible implementation of a ruggedized hydrogel product according to one embodiment. A patient 50 is shown undergoing an ultrasound imaging procedure with the use of an ultrasound imaging system 60, which includes a console 62 housing a display 64. An ultrasound probe 70, configured in accordance with one embodiment, is operably connected to the console 62 via a cable 72 or other suitable connective scheme and is positioned atop a portion of the patient's chest in order to provide ultrasonic images of a vessel or other subcutaneous features.

FIGS. 6A and 6B depict further details regarding the ultrasound probe 70 depicted in FIG. 5. The probe 70 has a general pancake shape and includes a flexible, annular perimeter portion 76 that is configured to be deformable. A reinforcement ring 78 is embedded within the perimeter portion 76 so as to limit the range of deformation for the probe 70. In one embodiment, the reinforcement ring 78 can be configured to maintain the deformation of the probe 70 when deformed by a clinician in order to conform to a particular body contour of the patient.

A transducer 80 is included in the central portion of the probe 70 such that it is bounded by the perimeter portion 76. In the present embodiment, the transducer 80 includes polyvinylidene fluoride ("pvdf"), which is a non-reactive and pure thermoplastic fluoropolymer that is also a piezoelectric material. As such, the pvdf material can serve as a transducer element for the transducer 80 in producing and detecting ultrasonic signals. Like the perimeter portion 76, the pvdf transducer is also flexible. The flexible nature of the perimeter portion 76 and the pvdf transducer 80 thus enables the probe to conform to body contours when it is placed upon the body of the patient.

FIG. 6B shows that the probe 70 further includes a hydrogel slab 90 that is positioned on a bottom surface of the transducer 80 so as to provide an acoustically transparent interface between the transducer and the body of the patient. In the present embodiment, the hydrogel slab 90 is manufactured as described herein so as to exhibit ruggedized characteristics and be able to withstand high-energy sterilization procedures. Thus, the hydrogel slab 90 of FIG. 6B shows one

example of an optional use of the ruggedized hydrogel product described herein in addition to implementations already described.

FIG. 7 shows the pancake ultrasound probe 70 according to another embodiment, wherein the transducer includes a plurality of discrete transducer elements 94 that are physically and electrically isolated separated from one another by insulating dividers 96 of plastic or other suitable material. These and other transducer designs are therefore contemplated. In one embodiment, the probe 70 is employed in an A-mode ultrasound imaging setting to detect the presence of pneumothorax in a patient following the placement of a catheter of other device into the vasculature of the patient in the case where the device has punctured the lung. Differences noted in the A-mode ultrasound profile of the subcutaneous area of interest before and after catheter placement can indicate the presence of pneumothorax. Of course, the probe can be employed in other applications.

Embodiments of the invention may be embodied in other specific forms without departing from the spirit of the present disclosure. The described embodiments are to be considered in all respects only as illustrative, not restrictive. The scope of the embodiments is, therefore, indicated by the appended claims rather than by the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.

What is claimed is:

1. A cap for an ultrasound probe, comprising:

a body defining a cavity into which a portion of an ultrasound probe is received; and

a ruggedized low-friction hydrogel insert operably attached to the body, the low-friction hydrogel insert comprising:

a gel component including carrageenan gum and konjac gum;

isopropyl alcohol;

deionized water; and

a free radical absorber component for absorbing free radicals produced when the low-friction hydrogel insert is subjected to a high-energy sterilization procedure, the free radical absorber component including at least one of potassium metabisulfite and ascorbic acid.

2. The cap as defined in claim 1, wherein the free radical absorber component includes both potassium metabisulfite and ascorbic acid.

3. An ultrasound probe, comprising

a body including a transducer; and

a ruggedized hydrogel product operably attached to the body to provide for a low friction interface, the hydrogel product comprising:

a gel component;

isopropyl alcohol;

deionized water; and

a free radical absorber component for absorbing free radicals produced if the hydrogel product is subjected to at least one of a gamma beam sterilization procedure and an electronic beam sterilization procedure.

4. The probe as defined in claim 3, wherein the free radical absorber component includes at least one of potassium metabisulfite and ascorbic acid and wherein the gel component includes a gum component.

5. The probe as defined in claim 3, wherein the probe is a flexible pancake probe and wherein the hydrogel product is slab-shaped and positioned on a bottom surface of the pancake probe.

6. The probe as defined in claim 5, wherein the pancake probe includes a flexible outer perimeter that bounds a flexible transducer, the transducer including polyvinylidene fluoride.

7. The probe as defined in claim 6, wherein the transducer is segmented into a plurality of discrete transducer elements.

* * * * *

专利名称(译)	坚固耐用的超声波水凝胶插入物		
公开(公告)号	US9211107	公开(公告)日	2015-12-15
申请号	US13/671382	申请日	2012-11-07
申请(专利权)人(译)	C. R. BARD , INC.		
当前申请(专利权)人(译)	C. R. BARD , INC.		
[标]发明人	COX JEREMY B SOUTHARD GLEN E MESSERLY SHAYNE		
发明人	COX, JEREMY B. SOUTHARD, GLEN E. MESSERLY, SHAYNE		
IPC分类号	A61K49/00 B29C39/00 A61B8/00 C08J3/075 A61K49/22 C08L5/00		
CPC分类号	A61B8/4281 A61B8/4444 A61B8/4483 B29C39/003 C08J3/075 C08L5/00 C08K5/005 A61K49/22 C08J2305/00		
代理机构(译)	鲁坦和塔克LLP		
审查员(译)	迪金森 , PAUL		
优先权	61/563382 2011-11-23 US 61/556626 2011-11-07 US		
其他公开文献	US20130116571A1		
外部链接	Espacenet USPTO		

摘要(译)

本发明公开了一种加固的水凝胶产品，其配制能够承受高能灭菌程序的影响，例如γ射线束和电子束灭菌，而没有显著的结构降解。这使得水凝胶产品能够适用于需要无菌组分的医疗应用。在一个实施方案中，公开了一种加固的水凝胶产品，其包含凝胶组分，用于使凝胶组分水合的水，和至少一种能够吸收当水凝胶产品通过高能灭菌消毒时产生的自由基的自由基吸收剂组分。程序。在一个实施方案中，自由基吸收剂组分包括偏亚硫酸氢钾和抗坏血酸。加固的水凝胶产品可以包括在超声探头中，以在探头和患者的皮肤之间提供声学透明的界面。

